Data-driven consideration of genetic disorders for global genomic newborn screening programs

Thomas Minten[1], Sarah Bick[2,3,4], Sophia Adelson[5,6], Nils Gehlenborg[7], Laura M. Amendola[8], François Boemer[9], Alison J. Coffey[10], Nicolas Encina[11,12,13], Alessandra Ferlini[14], Janbernd Kirschner[15], Bianca E. Russell[16], Laurent Servais[17,18], Kristen L. Sund[19], Ryan J. Taft[10], Petros Tsipouras[20], Hana Zouk[21,22,23], ICoNS Gene List Contributors**, David Bick[24], the International Consortium on Newborn Sequencing (ICoNS)***,
Robert C. Green[5,12,23,25]*, Nina B. Gold[26]*†

* These authors contributed equally to the manuscript.
† Corresponding author
** See Supplement A for list of ICoNS Gene List Contributors authors
*** See Supplement B for a list of International Consortium on Newborn Sequencing (ICoNS) authors

Address correspondence to: Nina B. Gold, MD, Mass General Hospital for Children, Division of Medical Genetics and Metabolism, 175 Cambridge Street, Boston, MA 02114, [ngold@mgh.harvard.edu]

[1]KU Leuven; [2]Boston Children's Hospital; [3]Massachusetts General Hospital; [4]Harvard Medical School; [5]Brigham and Women's Hospital; [6]Stanford School of Medicine; [7]Harvard Medical School, Department of Biomedical Informatics; [8]National Institutes of Health, National Institute of Allergy and Infectious Disease; [9]University of Liege, CHU Liege; [10]Illumina Inc.; [11]ICoNS; [12]Ariadne Labs; [13]Harvard T.H. Chan School of Public Health; [14]University of Ferrara, Department of Medical Sciences, Department of Medical Sciences, Unit of Medical Genetics; [15]University Medical Center Freiburg, Department of Neuropediatrics and Muscle Disorders; [16]University of California, Los Angeles, David Geffen School of Medicine, Department of Human Genetics, Division of Clinical Genetics; [17]University of Oxford; [18]University of Liege; [19]Nurture Genomics; [20]FirstSteps-BNSI; [21]Massachusetts General Hospital, Department of Pathology, Laboratory for Molecular Medicine; [22]Harvard Medical School, Department of Pathology; [23]Broad Institute; [24]Genomics England; [25]Mass General Brigham; [26]Massachusetts General Hospital, Department of Pediatrics; Harvard Medical School, Department of Pediatrics

Structured Abstract

Purpose: Over 30 international studies are exploring newborn sequencing (NBSeq) to expand the range of genetic disorders included in newborn screening. Substantial variability in gene selection across programs exists, highlighting the need for a systematic approach to prioritize genes.

Methods: We assembled a dataset comprising 25 characteristics about each of the 4,390 genes included in 27 NBSeq programs. We used regression analysis to identify several predictors of inclusion, and developed a machine learning model to rank genes for public health consideration.

Results: Among 27 NBSeq programs, the number of genes analyzed ranged from 134 to 4,299, with only 74 (1.7%) genes included by over 80% of programs. The most significant associations with gene inclusion across programs were presence on the US Recommended Uniform Screening Panel (inclusion increase of 74.7%, CI: 71.0%-78.4%), robust evidence on the natural history (29.5%, CI: 24.6%-34.4%) and treatment efficacy (17.0%, CI: 12.3%-21.7%) of the associated genetic disease. A boosted trees machine learning model using 13 predictors achieved high accuracy in predicting gene inclusion across programs (AUC = 0.915, R^2 = 84%).

Conclusion: The machine learning model developed here provides a ranked list of genes that can adapt to emerging evidence and regional needs, enabling more consistent and informed gene selection in NBSeq initiatives.

Introduction

A decade ago, the BabySeq Project piloted newborn and childhood sequencing (NBSeq), a process designed to detect risk for a wide range of genetic disorders in apparently healthy infants.[1–9] Per the data repository Rx-Genes, over 700 genetic disorders now have targeted treatments or consensus guidelines for long-term management, which has further fueled enthusiasm for NBSeq.[10,11] Stakeholders, including diverse groups of parents,[12–14] rare disease specialists,[11] primary care physicians,[15] genetic counselors,[11,16,17] and the public[18,19] now support the implementation of genomic newborn screening for at least some disorders. At least 30 international research programs and companies are actively exploring this screening approach,[20–22] most of which are exchanging best practices through the International Consortium on Newborn Sequencing (ICoNS).[23]

Historically, the criteria established by Wilson and Jungner[24] have provided a framework for selecting the disorders to include in public newborn screening programs. These criteria prioritize the inclusion of childhood-onset disorders that are treatable if diagnosed in their earliest stages and require immediate intervention to prevent irreversible damage. Given the hundreds of treatable disorders that could be candidates for NBSeq and the complexity of genomic data, however, selection of the appropriate genes and disorders for NBSeq is a recurring challenge.[21,25,26] Prior studies have identified discrepancies across the genes being analyzed by a limited number of commercial NBSeq programs[27] and research studies,[28,29] but little is known about the values and variables that underlie these differences. Understanding which genes have high concordance across programs may guide emerging NBSeq research programs as they select which genes and variants to report to participants. Furthermore, the characteristics of these genes and their associated disorders can be used more empirically to prioritize candidate genes for public health programs.

To understand the variability among newborn sequencing programs, we compared the genes currently selected for analysis by 27 research studies and commercial NBSeq

programs. For each gene that was included in any NBSeq program, we assembled a dataset of 25 associated characteristics. We then used a multivariate regression analysis to identify which of these characteristics were associated with inclusion across programs. Finally, we used a boosted trees model to generate a ranked list of genes, offering a data-driven approach to the prioritization of genetic disorders for population-wide NBSeq.

Materials and methods

Study design

This cross-sectional study involved four stages: (1) identification of gene lists across international NBSeq research studies and commercial programs, (2) compilation of a dataset of characteristics for each gene included in any program, (3) statistical comparison of gene lists across programs, and (4) development of a machine learning model to predict gene inclusion across NBSeq programs based on gene characteristics.

Identification of lists of genes from research studies and commercial programs

A total of 35 NBSeq programs were identified through membership in the International Consortium on Newborn Sequencing (ICoNS) and an online search (Supplementary Table S1, Figure 1).[5,30–47] We obtained gene lists from 27 NBseq programs, including 20 research studies: BabyDetect,[30,31] BabyScreen+,[28] BabySeq,[2] BeginNGS,[32,33] Chen et al. 2023,[34] Early Check,[35,48] FirstSteps, the Generation study, gnSTAR,[36,38] GUARDIAN study,[42,49,50] Jian et al. 2022,[37] Lee et al. 2019,[43] Luo et al. 2020,[44] NeoExome,[47] NeoSeq,[40] NESTS,[41] NewbornsInSA, Progetto Genoma Puglia, Screen4Care,[45] and Wang et al. 2023.[39] Seven lists of genes from commercial firms that offer genomic newborn screening were included: FORESITE 360 (Fore Genomics), Fulgent (Newborn Genetic Analysis), Igenomix (Igenomix newborn screening), Mendelics (Teste da Bochechinha), Nurture Genomics, PerkinElmer Revvity (Genetic InsightPanel),[46] and Sema4 (Natalis).[30] Nine studies reported screening outcomes and we also summarized the positive screen rates and positive predictive values for these studies (Table 1, Supplementary Methods).

Compilation of a dataset of gene-disorder characteristics

All obtained gene lists were aggregated, standardizing gene names to HGNC nomenclature and linking each gene to a single disorder using OMIM and ClinGen (Supplementary Methods). A data repository with 25 characteristics for each gene-disorder pair was created, collecting data from five research papers and five existing databases (see Supplementary Methods).[2,10,11,32,51–53] More information on the source and description of each of the characteristics can be found in the Supplementary Methods and Supplementary Table 3. This data repository as well as the gene list data were made available online in a Github Repository.

Statistical comparison of gene lists across programs

Descriptive statistics for each gene list, including the length of the list, proportion of genes in each clinical category, and the number of genes associated with RUSP conditions were calculated (Figure 2A, 2B, Supplementary Figure 2, and Supplementary Table 4). To provide information on the concordance across all lists of genes, an UpSet plot, Venn Diagrams, and Jaccard similarity indices were provided (Figure 2C and 2D, Supplementary Figure 3 and 4). Inclusion of high concordance genes, as well as genes associated with core and secondary RUSP conditions, were plotted (Figure 2E, 2F, 2G).

A linear regression model was used to identify factors associated with inclusion in multiple gene lists. Two types of regressions were performed: regressions in which the outcome variable is the proportion of gene list inclusion *across all NBSeq programs* (Figure 3A, Supplementary Table 5 and 6) and regressions in which the outcome variable is the inclusion of a gene for each *individual* study (Figure 3B and Supplementary Table 7).

Development of a machine learning model

We developed a machine learning prediction model to prioritize genes for population-wide

NBSeq programs. Out of 25 potential gene-disorder characteristics, we selected 13 characteristics as predictors in our model: the RUSP category, clinical area, evidence base, severity of the disorder, the treatment efficacy, penetrance, treatment acceptability, age of onset, existence of an orthogonal test, the recommendation score, inheritance, prevalence, and the ClinGen Disease Validity. The remaining 12 gene and disease characteristics were excluded due to a high amount of missing data. For example, the ClinGen actionability scores were not used due to their availability for only 242 genes. Additionally, when characteristics from different sources described similar concepts, we selected the characteristic that includes data on the most genes.

Three machine learning models were compared: linear regression, random forest and boosted trees. We randomly split the gene list data into a 80% training set (n=91,312, 80% of all 114,140 potential instances of 4,390 genes included on a gene list across 26 NBSeq programs) and a 20% test set to estimate prediction power of the model. The boosted trees model, which had the highest area under the curve (AUC), was then selected to generate predictions for all 4,390 genes, providing a ranked list of genes (Supplementary Table 8).

Results

Overview of NBSeq programs

Of the 35 research and commercial programs identified, 10 were located in North America, 10 in Asia, nine in Europe, four in Australia and New Zealand, one in South America and one in Africa (Figure 1, Supplementary Table 1). The research programs anticipate a combined total sample size of 560,410 infants, with the intended enrollment in each study varying from 48 to 101,000 infants.[43,54] Nine NBSeq research programs have published or presented the screening results from a collective total of 68,628 infants by September 2024 (Table 1, Supplementary Methods).

The percentage of positive screening results ranged from 1.85% in BabyDetect (3,847 infants screened for 405 genes) to 9.43% in BabySeq (159 infants screened for 4,299

genes), with an average of 3.82% positive results across 68,628 infants. There was a significant positive correlation between the percentage of positive screening results in a program and the number of genes they screened (pearson correlation coefficient of 0.653, p=0.041). A majority of the collective 1,937 positive screening results across seven studies for which detailed results were available were due to variants in *G6PD* (56.8%).

Four studies reported the clinical outcomes of infants who had undergone NBSeq, allowing for the calculation of these studies' positive predictive value (PPV), which varied from 12% to 79%[49,50] with an average across studies of 41% (39% when weighted by sample size).

Description of gene lists across NBSeq programs

A total of 23 programs have published or made available criteria for selecting genes and disorders for screening (Supplementary Table 2). The number of genes included in 27 programs ranged from 134 to 4,299 (median=306) (Figure 2A, 2B). A total of 4,390 genes (out of a total of 4,966 genes associated with human disease)[55] were included across at least one of the 27 gene lists (Supplementary Table 4). Of these, 4,033 genes (91.8%) were associated with a phenotype in the OMIM database. Collectively, most genes were linked to inherited metabolic disorders (IMDs) (25.4%), neurologic (15.5%), and immunologic (11.9%) disorders (Figure 2A, 2B).

Discordance among gene lists used in NBSeq programs

A pairwise Jaccard Index indicated that, aside from those from commercial laboratories, most pairs of gene lists from NBSeq research programs were highly discrepant (Figure 2C and 2D, Supplementary Figure 2, 3). Of the 4,390 genes included in at least one NBSeq program, the vast majority were included by only a small number of NBSeq programs: 4,089 genes (93%) were included by 10 or fewer programs and 3,793 (87%) genes were included by five or fewer programs (Supplementary Figure 1).

Genes with high concordance across NBSeq programs

Despite this variability across gene lists, we found 74 genes (1.7% of 4,390) that were included by over 80% (22 of 27) of NBSeq programs (Supplementary Figure 1). Of these genes, 58 were associated with diseases on the US Recommended Uniform Screening Panel (RUSP) (Figure 2E, 2F). A total of 34 genes not linked to disorders on the RUSP appeared on 20 or more lists (Figure 2G).

Predictors of gene inclusion across NBSeq programs

Genes associated with core or secondary disorders on the RUSP were significantly more likely to be included in NBSeq programs (regression coefficient 74.7%, 95% confidence interval (CI): 0.710-0.784, $p<0.01$; regression coefficient 60.0%, 95% CI: 0.557-0.643, $p<0.01$, Figure 3A, Supplementary Table 5). Additionally, genes that were recommended for inclusion in newborn screening by 80% or more rare disease experts in a recent survey[11] were 43.5% (95% CI: 37.4%-49.6%, $p<0.01$) more likely to be included than genes that were recommended by fewer experts (Supplementary Figure 5).

A strong predictor of inclusion across NBSeq programs was the ASQM evidence base, previously defined as a metric measuring a combination of gene-disease validity, published descriptions of the natural history of disease, and the availability of practice guidelines for disease diagnosis and management.[51] Genes with the highest evidence base were 29.5% more likely (95% CI: 24.6%-34.4%, $p<0.01$) to be included in NBSeq programs than those with less available evidence.

Other characteristics associated with inclusion across NBSeq programs were high efficacy of disease treatment (17.0%, 95% CI: 12.3%-21.7%, $p<0.01$), high penetrance (15.5%, 95% CI: 9.8%-21.2%, $p<0.01$), neonatal- or infantile-onset (15.2%, 95% CI: 10.7%-19.7%, $p<0.01$), high disease severity (14.5%, 95% CI: 8.2%-20.8%, $p<0.01$), high acceptability of

treatment (with regard to the burdens and risks placed on the individual) (15.0%, 95% CI: 10.5%-19.5%, $p<0.01$), and the existence of an non-molecular test that could be used to confirm the diagnosis (13.8%, 95% CI: 9.3%-18.3%, $p<0.01$). There was variability in the importance of different characteristics across programs, but programs adhered positive value to all these characteristics with few exceptions (Figure 3B and Supplementary Table 7).

Measuring evolving knowledge about genes and diseases

We conducted a multivariate regression analysis to predict how changes in specific variables, such as treatability and evidence base, would individually influence the overall regression (Supplementary Table 6). Notably, the introduction of a new, highly acceptable treatment for a disorder with no previous treatment is associated with an increase in the likelihood of inclusion in NBSeq programs by 9.7% (95% CI: 0.1%-19.3%, $p<0.05$). Similarly, improving knowledge related to the natural history of a gene-disorder pair from “none” to “perfect” would increase the likelihood of inclusion in NBSeq programs by 14.8% (95% CI: 4.8%-24.8%, $p<0.01$).

Machine learning prediction model

Of three machine learning methods, the boosted trees model demonstrated the highest accuracy in the hold-out test set, with an area under the curve (AUC) of 0.915 and R-squared of 80% (n=22,828, 20%) (Figure 3C, 3D). The relative importance of all variables in the boosted trees model was highest for characteristics such as the proportion of experts who recommended inclusion of the gene in NBSeq on a recent survey,[11] RUSP classification, and disease prevalence, confirming the results from the regression analysis (Supplementary Figure 8).

We used the boosted trees model to predict the observed inclusion of genes across all NBSeq programs, resulting in a list of all genes that had appeared in any NBSeq program,

ranked by their predicted inclusion probabilities. Given that most genes associated with conditions on the RUSP were highly ranked, a list with these genes redacted was considered to be more illustrative of the novel capabilities of the model (Table 2). This analysis identified five genes *(PTPRC, ACADSB, NHEJ1, CYBA, and GRHPR)* that, despite being highly ranked by the model, were only included in a low proportion of NBSeq programs. To address missing data for some genes that were included across multiple NBSeq programs, we also created a second ranked list that combines the rankings generated by our machine learning model with the proportion of NBSeq programs in which each gene was observed with equal weights (Supplementary Table 8). By integrating these two sources of information, this hybrid list leverages the most comprehensive evidence available to prioritize genes for potential implementation in public health programs.

Discussion

NBSeq is a rapidly advancing area of global research exploring the impacts of early diagnosis for infants at risk for genetic disorders. With positive screening results in 1.85% to 9.43% of infants and a higher average PPV than some traditional newborn screening techniques,[49,56] findings from NBSeq research programs support the premise that this approach could improve early detection rates for a wide range of treatable disorders. However, selecting the appropriate genes for screening is a critical step toward implementing population-wide NBSeq. This decision will have significant implications for at-risk infants, their families, and pediatric healthcare systems.[20,21] In this study, we compared and collected data on the genes being analyzed by 27 NBSeq programs, then developed a machine learning model to predict the inclusion of a gene across NBSeq programs. By combining this model with observed data from NBSeq programs, we generated a ranked list of genes that offers a data-driven approach to prioritizing genetic disorders for public health programs looking to incorporate NBSeq into their screening strategies.

Similar to the findings of smaller studies,[28,29] our comparison of gene lists from 27 NBSeq programs revealed substantial heterogeneity, which we probed using a series of regression models. We found that the importance of individual gene and disease characteristics varied across studies, potentially due to differences in the international prevalence of disorders, the availability of specialists and treatments in different countries and healthcare systems, or the specific goals of individual NBSeq programs. Unexpectedly, 357 genes with no disease association on OMIM and 52 with limited or refuted gene-disease validity scores from ClinGen were included by some NBSeq programs, demonstrating variation among programs in willingness to include candidate genes or those with new associations to disease.

Despite variations in the gene lists used by NBSeq programs, many share a common focus on certain clinical areas and specific genes. All programs included a substantial proportion of genes associated with disorders that are on the RUSP, reflecting the potential for genomic sequencing to detect cases missed by traditional newborn screening programs.[57–59] Of note, genes associated with some disorders on the RUSP, such as 3-methyl-crotonyl-CoA carboxylase deficiency (*MCCC1*, *MCCC2*), were widely included across lists despite not conforming to the historic Wilson-Jungner criteria, due to low penetrance and often mild symptoms.[60] This suggests that some NBSeq programs have anchored their lists around the RUSP even when the disorders are neither severe nor highly treatable.[61] Therefore, the observed concordance of a gene across NBSeq programs alone may not be sufficient to evaluate the suitability of a gene for population-wide screening.

Many gene and disease characteristics emerged as highly associated with the inclusion of genes across NBSeq programs, including the strength of published data on the natural history of disease, estimated penetrance, and the effectiveness of the associated treatment. Interestingly, despite the inclusion criteria that several NBSeq programs reported, characteristics such as the age of onset and disease severity were weakly associated with inclusion, possibly due to their subjective nature.

The machine learning model developed in this study identifies the disorders that may be most appropriate for genomic newborn screening, based on 13 characteristics and their inclusion across 27 NBSeq programs. This ranked list, along with the preferences of rare disease experts[11] could be used to prioritize genes for screening, which could then be manually curated by a team of expert reviewers. At this time, the model's predictions reflect a consensus drawn from NBSeq studies and databases, but in the future, these could be combined with hard-coded gene selection criteria. The model's flexibility also allows updates based on regional preferences, new data, or emerging therapeutics.

Importantly, this model identified several genes included by only a few NBSeq programs, but which have characteristics that are highly associated with inclusion across programs. For example, although *PTPRC*, a gene associated with severe combined immunodeficiency (SCID), was only included by 12 of 27 NBSeq programs, the model ranked it 113 of 4,390 genes. This is likely because *PTPRC* is associated with a severe immunologic disorder that typically presents in childhood and can be treated with an early hematopoietic stem cell transplant, but is a rare cause of SCID.[62] This finding highlights the model's potential to identify genes that may have been overlooked by researchers during the gene selection process.

Our study has several limitations. First, some of the NBSeq programs may have dynamic gene lists that have changed over time. Second, the treatability of various conditions varies based on country. Next, the Jaccard index may exaggerate discrepancies between gene lists of different lengths. For the regression and machine learning models, we consolidated metrics including the ASQM, BabySeq, and ClinGen databases, most of which rely on expert-curated information, such as age of onset, for which definitions vary, and data were missing among the 25 characteristics that we collected. These gaps may automatically reduce the boosted tree model's predicted inclusion of genes that are not well-characterized,

resulting in lower inclusion rates for genes related to disorders that are rare or have limited published evidence. To mitigate the effects of missing data, we designed the model to be easily updated, and provided a ranked gene list that takes into account observed inclusion in addition to our model estimates. The ranked list may suffer from overfitting, given that it includes genes on which the model was trained. Lastly, the model incorporates data from funded research programs and commercial products, which may not align with the goals or constraints of public health newborn screening programs.

In the future, we plan to further develop the dataset that we have created to improve our machine learning model, by incorporating the perspectives of key informants, such as parents[13,14] and pediatricians. Additional informatics data, such as gene length, gnomAD constraint score,[63] the ENCODE blacklist,[64] or the number of associated PubMed publications, will be updated in future versions. We also plan to develop a method to iteratively add genes with newly established gene-disease validity based on recent publications to our dataset. Future research will identify genes that are not currently included in any NBSeq program, but share similar characteristics to those that are highly represented. A knowledge graph, such as PrimeKG,[65] could be used to find genes that share common molecular pathways, treatments, or symptoms to genes that are currently included in our dataset.

In summary, the growing international interest in genomic newborn screening has prompted important questions about which genes and disorders should be considered for inclusion. Due to the substantial variation in the genes included by 27 NBSeq programs, we developed an evidence-based approach to considering gene selection that draws from a comprehensive data repository encompassing over 4,000 genes. Rather than creating a static list of genes for universal implementation, our dynamic ranking system is adaptable and can be updated as new knowledge about genes, disorders, and therapeutics emerges.

This work will support gene selection for both research and public health programs considering the use of population-wide NBSeq.

Figures

Figure 1. Research and commercial genomic newborn screening (NBSeq) programs. Gene lists from 27 of these programs were included in the analysis (denoted with an asterisk). Intended enrollment sizes are indicated where available.



Figure 2. Description, concordance and content of gene lists of genomic newborn screening programs.

A. Clinical areas of 4,299 genes included in BabySeq.
B. Counts and clinical areas of genes included in 26 research and commercial genomic newborn screening programs (n=4,390).
C. Jaccard similarity index, which offers a quantitative comparison of how closely related the gene lists are.
D. UpSet plot[65] of gene lists of 4 large research studies. The matrix below the bar graph represents each individual study and their intersections (n=818).
E. Inclusion of genes associated with core Recommended Uniform Screening Panel (RUSP) conditions. The x-axis is each genomic newborn screening program and y-axis are individual genes; the corresponding cell is colored if the gene is included on a given list.
F. Inclusion of genes associated with secondary RUSP conditions.
G. Inclusion of genes on 20 lists or more that are not associated with RUSP conditions.


A.
BabySeq, 4,299 genes
480
1242
250
348
183
547
243
142
120
259
122
75
66
119
103
B.
Number of genes
Metabolism
Endocrinology
Cardiovascular
Ophthalmology
Pulmonology
Neurology
Hematology
ENT/Dental
Oncology
Orthopedics
Immunology
Medical Genetics
Nephrology
Gastroenterology
Dermatology
NewbornsInSA
BabyScreen+
NeoExome
Luo et al. 2020
Generation Study
NESTS
BabyDetect
Genoma Puglia
FirstSteps
BeginNGS
GUARDIAN Study
Jian et al. 2022
Screen4Care
Lee et al. 2019
Early Check
Wang et al. 2023
Chen et al. 2023
NeoSeq
GNSTAR
Nurture
FORESITE 360
Mendelics
PerkinElmer
Fulgent
Igenomix
Semaf
Research studies
Commercial programs
C.
Jaccard Index
D.
Number of genes
GUARDIAN
BabyDetect
Generation
NewbornsInSA
Size of gene list
E.
F.
G.
Metabolism
Endocrinology
Cardiovascular
Ophthalmology
Pulmonology
Neurology
Hematology
ENT/Dental
Oncology
Orthopedics
Immunology
Medical Genetics
Nephrology
Gastroenterology
Dermatology

Figure 3. Determinants and prediction model of gene inclusion in genomic newborn screening. In a and b, RUSP category (n=4,474), survey recommendation and orthogonal test (n=649), evidence base, efficacy, penetrance, disease severity, treatment acceptability and neonatal or infant onset (n=749). ROC, Receiver Operating Characteristic; AUC, Area Under the Curve.

A. Regression coefficients (and confidence intervals) associated with various gene and disease characteristics predicting inclusion across gene lists.
B. Heat map with regression coefficients associated with gene and disease characteristics for each individual genomic newborn screening program.
C. ROC curves for three prediction models in the hold-out test set (n=895 genes).
D. Scatter plot of predicted versus observed gene list inclusion, showing the fit of the boosted trees model on the 20% hold-out set (n=895 genes).



Tables

Table 1. Percentage of positive results from genomic newborn screening research programs. Positive cases of *G6PD,* as well as follow-up data for positively screened infants reported where available. PPV, positive predictive value.

		Sequencing data				Follow-up data		
NBSeq research study	Genes	Infants sequenced	G6PD deficiency	Total positive	Total positive (in %)	Total follow-up	Total diagnosed	PPV
BabyDetect	405	3,847	44	71	1.85%			
PerkinElmer Panel	268	606	4	13	2.15%			
Wang et al. 2023	164	10,334		232	2.25%	231	50	22%
gnSTAR	134	4,986	40	113	2.27%			
Chen et al. 2023	142	29,601	689	813	2.75%	797	402	50%
GUARDIAN Study	237	4,000		147	3.68%	151	120	79%
NESTS	465	11,484	338	902	7.85%	414	50	12%
PerkinElmer GS	6,000	562	4	46	8.19%			
NeoExome	601	3,049		271	8.89%			
BabySeq	4,299	159	1	15	9.43%			
TOTAL		**68,628**		**2,623**	**3.82%**			

Table 2. List of 50 genes with highest predicted inclusion across NBSeq programs, excluding genes on the Recommend Uniform Screening Panel (RUSP). ASQM, Age-Based Semi Quantitative Metric.

Rank	Gene	Disorder	OMIM Phenotype	Clinical area	BabySeq category	ClinGen validity	ClinGen Actionability (/12)	ASQM score (/15)	Expert Recommendation	Observed list inclusion (/27)	Predicted list inclusion
13	*G6PC1*	Glycogen storage disease Ia	232200	Metabolism	A			13	93%	26	96%
17	*OTC*	Ornithine transcarbamylase deficiency	311250	Metabolism	A	Definitive	10AB	14	98%	26	96%
40	*SLC37A4*	Glycogen storage disease Ib	232220	Metabolism	A			13	93%	25	91%
41	*CPS1*	Carbamoylphosphate synthetase I deficiency	237300	Metabolism	A	Definitive	9AB	13	86%	25	90%
47	*SLC25A15*	Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome	238970	Metabolism	A	Definitive		10	85%	25	88%
51	*AGL*	Glycogen storage disease IIIa	232400	Metabolism	A	Definitive		12	85%	24	86%
52	*NAGS*	N-acetylglutamate synthase deficiency	237310	Metabolism	A	Definitive	10NC	14	85%	22	86%
55	*ALPL*	Hypophosphatasia, infantile	241500	Endocrinology	A	Definitive	10CC	11	71%	23	84%
56	*GALNS*	Mucopolysaccharidosis IVA	253000	Metabolism	A	Definitive	9CA	9	87%	23	84%
57	*ALDOB*	Fructose intolerance, hereditary	229600	Metabolism	A		10NC	14	84%	23	83%
60	*BTK*	Agammaglobulinemia, X-linked 1	300755	Immunology	A	Definitive			81%	24	82%
65	*F9*	Hemophilia B	306900	Hematology	A	Definitive	9CB	14	90%	23	81%
68	*CYBB*	Chronic granulomatous disease, X-linked	306400	Immunology	A			12	74%	25	80%
69	*G6PD*	Hemolytic anemia, G6PD deficient (favism)	300908	Hematology	A	Definitive	7DC	12	80%	23	80%
73	*CYP11B1*	Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency	202010	Endocrinology	A			11	92%	21	79%
74	*SMPD1*	Niemann-Pick disease	257200	Metabolism	A	Definitive		9	85%	21	78%

75	*ARSB*	Mucopolysaccharidosis type VI (Maroteaux-Lamy)	253200	Metabolism	A	Definitive		11	92%	22	77%
76	*CTNS*	Cystinosis, nephropathic	219800	Nephrology	A	Definitive	9CB	14	80%	20	77%
77	*ATP7B*	Wilson disease	277900	Metabolism	A	Definitive	11CA	12	81%	21	77%
78	*CYBA*	Chronic granulomatous disease 4, autosomal recessive	233690	Immunology	A			12	74%	18	77%
79	*ABCC8*	Hyperinsulinemic hypoglycemia, familial, 1	256450	Endocrinology	A	Definitive		14	81%	20	75%
80	*RB1*	Retinoblastoma	180200	Oncology	A	Definitive	10CB	13	89%	21	75%
81	*ALDH7A1*	Epilepsy, early-onset, 4, vitamin B6-dependent	266100	Neurology		Definitive	11CB	12	86%	21	74%
82	*TG*	Thyroid dyshormonogenesis 3	274700	Endocrinology	A			14		18	73%
84	*TPO*	Thyroid dyshormonogenesis 2A	274500	Endocrinology	A			14		18	71%
85	*PHEX*	Hypophosphatemic rickets, X-linked dominant	307800	Endocrinology			9CC		74%	20	71%
86	*TH*	Segawa syndrome, recessive	605407	Neurology	A	Definitive		13	70%	20	71%
87	*ATP7A*	Menkes disease	309400	Metabolism	A	Definitive	9CA	12	84%	19	71%
89	*SLC2A1*	GLUT1 deficiency syndrome 1, infantile onset, severe	606777	Metabolism	A	Definitive		11	90%	19	71%
90	*GLA*	Fabry disease	301500	Metabolism	A	Definitive	9CA	12	83%	20	70%
91	*DUOX2*	Thyroid dyshormonogenesis 6	607200	Endocrinology	A			13		20	70%
92	*WAS*	Wiskott-Aldrich syndrome	301000	Immunology	A	Definitive	9CC		68%	20	69%
93	*FBP1*	Fructose-1,6-bisphosphatase deficiency	229700	Metabolism				13	80%	18	69%
94	*PYGL*	Glycogen storage disease VI	232700	Metabolism	A			10	83%	19	69%
96	*SPR*	Dystonia, dopa-responsive, due to sepiapterin reductase deficiency	612716	Neurology	A	Definitive		12	70%	20	69%
97	*CD40LG*	Immunodeficiency, X-linked, with hyper-IgM	308230	Immunology	A	Definitive		11	74%	17	68%
98	*LIPA*	Wolman disease	620151	Metabolism	A	Definitive		7	80%	19	67%
100	*GUSB*	Mucopolysaccharidosis VII	253220	Metabolism	A	Definitive		9	89%	19	67%

101	*SCNN1B*	Pseudohypoaldosteronism, type IB2, autosomal recessive	620125	Endocrinology	A		14	49%	17	66%
102	*POU1F1*	Pituitary hormone deficiency, combined or isolated, 1	613038	Endocrinology	A		12	66%	18	66%
103	*TSHR*	Hypothyroidism, congenital, nongoitrous, 1	275200	Endocrinology	A		12		24	66%
104	*AVPR2*	Diabetes insipidus, nephrogenic, 1	304800	Endocrinology	A		11	60%	18	66%
105	*KCNJ11*	Diabetes mellitus, transient neonatal 3	610582	Endocrinology	A	Definitive	12	76%	18	64%
106	*GATM*	Cerebral creatine deficiency syndrome 3	612718	Metabolism		Definitive	10	85%	17	64%
108	*GLUD1*	Hyperinsulinism-hyperammonemia syndrome	606762	Metabolism	A	Definitive	11	87%	18	63%
110	*PHKB*	Phosphorylase kinase deficiency of liver and muscle, autosomal recessive	261750	Metabolism	A	Definitive	13	76%	17	63%
111	*CYP17A1*	17,20-lyase deficiency, isolated	202110	Endocrinology				90%	18	62%
114	*NPC1*	Niemann-Pick disease	257220	Metabolism	A	Definitive	12	69%	19	62%
115	*SLC7A7*	Lysinuric protein intolerance	222700	Metabolism	A	Definitive	12	85%	16	62%
116	*PROP1*	Pituitary hormone deficiency, combined, 2	262600	Endocrinology	A		13	66%	19	62%

References and notes

1. Waisbren SE, Bäck DK, Liu C, et al. Parents are interested in newborn genomic testing during the early postpartum period. *Genet Med*. 2015;17(6):501-504.

2. Ceyhan-Birsoy O, Machini K, Lebo MS, et al. A curated gene list for reporting results of newborn genomic sequencing. *Genet Med*. 2017;19(7):809-818.

3. Genetti CA, Schwartz TS, Robinson JO, et al. Parental interest in genomic sequencing of newborns: enrollment experience from the BabySeq Project. *Genet Med*. 2019;21(3):622-630.

4. Holm IA, Agrawal PB, Ceyhan-Birsoy O, et al. The BabySeq project: implementing genomic sequencing in newborns. *BMC Pediatr*. 2018;18(1):225.

5. Ceyhan-Birsoy O, Murry JB, Machini K, et al. Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project. *Am J Hum Genet*. 2019;104(1):76-93.

6. Pereira S, Smith HS, Frankel LA, et al. Psychosocial Effect of Newborn Genomic Sequencing on Families in the BabySeq Project: A Randomized Clinical Trial. *JAMA Pediatr*. 2021;175(11):1132-1141.

7. Pereira S, Robinson JO, Gutierrez AM, et al. Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project. *Pediatrics*. 2019;143(Suppl 1):S6-S13.

8. Green RC, Shah N, Genetti CA, et al. Actionability of unanticipated monogenic disease risks in newborn genomic screening: Findings from the BabySeq Project. *Am J Hum Genet*. 2023;110(7):1034-1045.

9. Smith HS, Zettler B, Genetti CA, Hickingbotham MR, Coleman TF, Lebo M, Nagy A, Zouk H, Mahanta L, Christensen KD, Pereira S, Shah ND, Gold NB, Walmsley S, Edwards S, Homayouni R, Krasan GP, Hakonarson H, Horowitz CR, Gelb BD, Korf BR, McGuire AL, Holm IA, Green RC. The BabySeq Project: A Clinical Trial of Genome Sequencing in a Diverse Cohort of Infants. *Am J Hum Genet, In Press*. Published online 2024.

10. Bick D, Bick SL, Dimmock DP, Fowler TA, Caulfield MJ, Scott RH. An online compendium of treatable genetic disorders. *Am J Med Genet C Semin Med Genet*. 2021;187(1):48-54.

11. Gold NB, Adelson SM, Shah N, et al. Perspectives of Rare Disease Experts on Newborn Genome Sequencing. *JAMA Netw Open*. 2023;6(5):e2312231.

12. Joseph G, Chen F, Harris-Wai J, Puck JM, Young C, Koenig BA. Parental Views on Expanded Newborn Screening Using Whole-Genome Sequencing. *Pediatrics*. 2016;137 Suppl 1(Suppl 1):S36-S46.

13. Timmins GT, Wynn J, Saami AM, Espinal A, Chung WK. Diverse Parental Perspectives of the Social and Educational Needs for Expanding Newborn Screening through Genomic Sequencing. *Public Health Genomics*. Published online September 15, 2022:1-8.

14. Gold NB, Omorodion JO, Del Rosario MC, et al. Preferences of parents from diverse

backgrounds on genomic screening of apparently healthy newborns. *J Genet Couns*. Published online October 28, 2024. doi:10.1002/jgc4.1994

15. Acharya K, Ackerman PD, Ross LF. Pediatricians' attitudes toward expanding newborn screening. *Pediatrics*. 2005;116(4):e476-e484.

16. Cao M, Notini L, Ayres S, Vears DF. Australian healthcare professionals' perspectives on the ethical and practical issues associated with genomic newborn screening. *J Genet Couns*. 2023;32(2):376-386.

17. del Rosario MC, Swenson KB, Coury S, Schwab J, Green RC, Gold NB. Genetic counselors' perspectives on genomic screening of apparently healthy newborns in the United States. *Genetics in Medicine Open*. 2024;(101885):101885.

18. Bombard Y, Miller FA, Hayeems RZ, et al. Public views on participating in newborn screening using genome sequencing. *Eur J Hum Genet*. 2014;22(11):1248-1254.

19. Lynch F, Best S, Gaff C, et al. Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation. *Screening*. 2024;10(1). doi:10.3390/ijns10010006

20. Stark Z, Scott RH. Genomic newborn screening for rare diseases. *Nat Rev Genet*. 2023;24(11):755-766.

21. Downie L, Halliday J, Lewis S, Amor DJ. Principles of Genomic Newborn Screening Programs: A Systematic Review. *JAMA Netw Open*. 2021;4(7):e2114336.

22. Bros-Facer V, Taylor S, Patch C. Next-generation sequencing-based newborn screening initiatives in Europe: an overview. *Rare Dis Orphan Drugs J*. 2023;2:21.

23. International Consortium on Newborn Sequencing. https://www.iconseq.org/

24. Wilson JMG, Jungner G. *The Principles and Practice of Screening for Disease*.; 1966.

25. Bick D, Ahmed A, Deen D, et al. Newborn Screening by Genomic Sequencing: Opportunities and Challenges. *Screening*. 2022;8(3). doi:10.3390/ijns8030040

26. Baple EL, Scott RH, Banka S, et al. Exploring the benefits, harms and costs of genomic newborn screening for rare diseases. *Nat Med*. 2024;30(7):1823-1825.

27. DeCristo DM, Milko LV, O'Daniel JM, et al. Actionability of commercial laboratory sequencing panels for newborn screening and the importance of transparency for parental decision-making. *Genome Med*. 2021;13(1):50.

28. Downie L, Bouffler SE, Amor DJ, et al. Gene selection for genomic newborn screening: moving towards consensus? *Genet Med*. Published online January 23, 2024:101077.

29. Betzler IR, Hempel M, Mütze U, et al. Comparative analysis of gene and disease selection in genomic newborn screening studies. *J Inherit Metab Dis*. Published online May 16, 2024. doi:10.1002/jimd.12750

30. Dangouloff T, Hovhannesyan K, Piazzon F, et al. Baby detect: Universal genomic newborn screening for early, treatable, and severe conditions. *J Neurol Sci*. 2023;455. doi:10.1016/j.jns.2023.121259

31. Website. "Population-Based, First-Tier Genomic Newborn Screening in a Single Maternity Ward in Belgium: Results of Babydetect Project." n.d. Accessed August 8,

2024. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4896054

32. Kingsmore SF, Smith LD, Kunard CM, et al. A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases. *Am J Hum Genet*. 2022;109(9):1605-1619.

33. Owen MJ, Lefebvre S, Hansen C, et al. An automated 13.5 hour system for scalable diagnosis and acute management guidance for genetic diseases. *Nat Commun*. 2022;13(1):4057.

34. Chen T, Fan C, Huang Y, et al. Genomic Sequencing as a First-Tier Screening Test and Outcomes of Newborn Screening. *JAMA Netw Open*. 2023;6(9):e2331162.

35. Bailey DB Jr, Gehtland LM, Lewis MA, et al. Early Check: translational science at the intersection of public health and newborn screening. *BMC Pediatr*. 2019;19(1):238.

36. Huang X, Wu D, Zhu L, et al. Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates. *Orphanet J Rare Dis*. 2022;17(1):66.

37. Jian M, Wang X, Sui Y, et al. A pilot study of assessing whole genome sequencing in newborn screening in unselected children in China. *Clin Transl Med*. 2022;12(6):e843.

38. Yang RL, Qian GL, Wu DW, et al. A multicenter prospective study of next-generation sequencing-based newborn screening for monogenic genetic diseases in China. *World J Pediatr*. 2023;19(7):663-673.

39. Wang X, Sun Y, Guan XW, et al. Newborn genetic screening is highly effective for high-risk infants: A single-centre study in China. *J Glob Health*. 2023;13:04128.

40. Wang H, Yang Y, Zhou L, Wang Y, Long W, Yu B. NeoSeq: a new method of genomic sequencing for newborn screening. *Orphanet J Rare Dis*. 2021;16(1):481.

41. Hao C, Guo R, Hu X, et al. Newborn screening with targeted sequencing: a multicenter investigation and a pilot clinical study in China. *J Genet Genomics*. 2022;49(1):13-19.

42. Chung WK, Kanne SM, Hu Z. An Opportunity to Fill a Gap for Newborn Screening of Neurodevelopmental Disorders. *Screening*. 2024;10(2). doi:10.3390/ijns10020033

43. Lee H, Lim J, Shin JE, et al. Implementation of a Targeted Next-Generation Sequencing Panel for Constitutional Newborn Screening in High-Risk Neonates. *Yonsei Med J*. 2019;60(11):1061-1066.

44. Luo X, Sun Y, Xu F, et al. A pilot study of expanded newborn screening for 573 genes related to severe inherited disorders in China: results from 1,127 newborns. *Ann Transl Med*. 2020;8(17):1058.

45. Ferlini A, Gross ES, Garnier N, Screen4Care consortium. Rare diseases' genetic newborn screening as the gateway to future genomic medicine: the Screen4Care EU-IMI project. *Orphanet J Rare Dis*. 2023;18(1):310.

46. Balciuniene J, Liu R, Bean L, et al. At-Risk Genomic Findings for Pediatric-Onset Disorders From Genome Sequencing vs Medically Actionable Gene Panel in Proactive Screening of Newborns and Children. *JAMA Netw Open*. 2023;6(7):e2326445.

47. Cao Z, He X, Wang D, et al. Targeted exome sequencing strategy (NeoEXOME) for Chinese newborns using a pilot study with 3423 neonates. *Mol Genet Genomic Med*.

2024;12(1):e2357.

48. Cope HL, Milko LV, Jalazo ER, et al. A systematic framework for selecting gene-condition pairs for inclusion in newborn sequencing panels: Early Check implementation. *Genet Med*. Published online October 4, 2024:101290.

49. Chung W, Ziegler A, Koval-Burt C, et al. O35: Feasibility of expanded newborn screening using genome sequencing for early actionable conditions in a diverse city. *Genetics in Medicine Open*. 2024;2(101369):101369.

50. Ziegler A, Koval-Burt C, Kay D, et al. Expanded newborn screening using genome sequencing for early actionable conditions. *JAMA*. Published online October 24, 2024. doi:10.1001/jama.2024.19662

51. Milko LV, O'Daniel JM, DeCristo DM, et al. An Age-Based Framework for Evaluating Genome-Scale Sequencing Results in Newborn Screening. *J Pediatr*. 2019;209:68-76.

52. Berg JS, Foreman AKM, O'Daniel JM, et al. A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing. *Genet Med*. 2016;18(5):467-475.

53. Rehm HL, Berg JS, Brooks LD, et al. ClinGen--the Clinical Genome Resource. *N Engl J Med*. 2015;372(23):2235-2242.

54. Spiekerkoetter U, Bick D, Scott R, et al. Genomic newborn screening: Are we entering a new era of screening? *J Inherit Metab Dis*. 2023;46(5):778-795.

55. Amberger JS, Bocchini CA, Schiettecatte FJM, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. *Nucleic Acids Res*. 2015 Jan;43(Database issue):D789-98.

56. Kwon C, Farrell PM. The magnitude and challenge of false-positive newborn screening test results. *Arch Pediatr Adolesc Med*. 2000;154(7):714-718.

57. Wojcik MH, Zhang T, Ceyhan-Birsoy O, et al. Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project. *Genet Med*. 2021;23(7):1372-1375.

58. Adhikari AN, Gallagher RC, Wang Y, et al. The role of exome sequencing in newborn screening for inborn errors of metabolism. *Nat Med*. 2020;26(9):1392-1397.

59. Cook S, Dunn E, Kornish J, et al. Molecular testing in newborn screening: VUS burden among true positives and secondary reproductive limitations via expanded carrier screening panels. *Genet Med*. 2023;26(4):101055.

60. Arnold GL, Koeberl DD, Matern D, et al. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. *Mol Genet Metab*. 2008;93(4):363-370.

61. Forsyth R, Vockley CW, Edick MJ, et al. Outcomes of cases with 3-methylcrotonyl-CoA carboxylase (3-MCC) deficiency - Report from the Inborn Errors of Metabolism Information System. *Mol Genet Metab*. 2016;118(1):15-20.

62. Roberts JL, Buckley RH, Luo B, et al. CD45-deficient severe combined immunodeficiency caused by uniparental disomy. *Proc Natl Acad Sci U S A*. 2012;109(26):10456-10461.

63. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443.

64. Amemiya HM, Kundaje A, Boyle A. The ENCODE blacklist: Identification of problematic regions of the genome. *Sci Rep*. 2019;9. doi:10.1038/s41598-019-45839-z

65. Chandak P, Huang K, Zitnik M. Building a knowledge graph to enable precision medicine. *Sci Data*. 2023;10(1):67.

66. Population-Based, First-Tier Genomic Newborn Screening in a Single Maternity Ward in Belgium: Results of Babydetect Project. Accessed August 8, 2024. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4896054

67. Seal RL, Braschi B, Gray K, et al. Genenames.org: the HGNC resources in 2023. *Nucleic Acids Res*. 2023;51(D1):D1003-D1009.

68. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. *Bioinformatics*. 2017;33(18):2938-2940.

Supplementary Methods

Description of gene lists of genomic newborn screening programs

We obtained gene lists from 27 NBseq programs, including 20 research studies, and seven companies. The 20 research studies are: BabyDetect,[30,66] BabyScreen+,[28] BabySeq,[2] BeginNGS,[32,33] Chen et al. 2023,[34] Early Check,[35,48] FirstSteps, the Generation study, gnSTAR,[36,38] GUARDIAN study,[42,49,50] Jian et al. 2022,[37] Lee et al. 2019,[43] Luo et al. 2020,[44] NeoExome,[47] NeoSeq,[40] NESTS,[41] NewbornsInSA, Progetto Genoma Puglia, Screen4Care,[45] and Wang et al. 2023.[39] In two studies (GUARDIAN and Early Check), all infants receive testing for a gene list focused on conditions with effective treatments and parents have the option to be tested for an expanded gene list. For both of these studies, we included only the core gene list focused on treatable genetic conditions. Seven lists of genes from commercial firms that offer products related to genomic newborn screening were included: FORESITE 360, Fulgent, Igenomix, Mendelics, Nurture Genomics, PerkinElmer (now Revvity),[46] and Sema4.[30] Of note, the Sema4 product is no longer commercially available.

Rates of positive screening results

A total of nine studies had published or presented results on positive screening results as of September 2024. As studies had different approaches to participant selection, we only reported results of NBSeq programs that screen apparently healthy infants. We excluded results from samples where specifically at-risk infants (such as those in the neonatal intensive care unit) were sequenced. From the Wang *et al* study, only the results on healthy infants were retained.[39] From the BabySeq study, we included both the healthy and NICU infant sample, as only unanticipated results unconnected with NICU clinical presentations were described for the NICU sample.[5] We excluded a sample from the NeoEXOME study of neonates that had positive results in conventional NBS.[47]

Aggregation of gene lists

Gene names were converted to the current nomenclature set forth by the HUGO Gene Nomenclature Committee (HGNC) based on an available online multi-symbol checker.[67] For purposes of analysis, each gene was linked to one condition. The multistep process for linking genes to a single disorder began by first identifying the phenotypes associated with each gene on Online Inheritance in Man (OMIM).[55] If only one disease name was associated with the gene on OMIM, a gene-disease pair was formed. If the gene was known to be associated with multiple OMIM disorders, we used the ClinGen gene-disease validity resource to select only the disorder with definitive classification when available.[53] For genes with more than one disorder with definitive validity or for genes without any disorder with definite validity, one disorder was selected based on the highest number of programs in this study that indicated it as screening target. For example, for *RYR1*, which has a definitive association with both susceptibility to malignant hyperthermia and myopathy,[53] susceptibility to malignant hyperthermia was selected as the target disorder. Susceptibility to malignant hyperthermia was indicated as a target disease by five of seven programs with disease information available screening for this gene, compared with myopathy which was listed as a target disease by only two of seven programs. A total of 264 genes were not annotated with disorder information from either ClinGen or OMIM databases, possibly because they were candidate genes or had very recently been substantiated as disease genes. These were then manually matched to diseases by search in HGMD (https://www.hgmd.cf.ac.uk/ac/index.php). Two gene names, *GTM* and *CD1*, which could not be linked to HGNC approved gene names, were omitted from the analysis.

Establishing a data repository of characteristics of genes-disorder pairs

We established a data repository consisting of 25 characteristics for all gene-disorder pairs, sourced from ten different references: five research papers and five existing databases.[2,10,11,32,51–53] Matching of data from these databases was based on finding an exact match with the gene-disorder pair. Matches were then manually checked for correctness. Three variables (prevalence, clinical area, and RUSP category) were newly

constructed for this study and were based on consolidated information from varying sources. Supplementary Table 3 provides an overview of all variables, as well as a description of all metrics and their respective sources.

To determine whether each gene-disease pair was associated with a disorder listed on the United States Recommended Uniform Screening Panel (RUSP), we cross-referenced the genes identified by Owen *et al*[33] with the diseases listed on the RUSP section of the United States Health Resources and Services Administration (HRSA) website (https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp). A gene was considered associated with a RUSP-listed disease if it appeared in the "Cause" section of the corresponding disease-specific HRSA webpage.

Each gene and its associated condition was assigned to one of 12 clinical areas. Although this methodology may not reflect the pleiotropic nature of each disease, the co-authors attempted to identify which pediatric specialist may act as the primary coordinator of an affected child's care, and which clinical specialty would therefore be most affected by the expansion of NBSeq. The clinical areas included cardiovascular, dermatology, ENT/Dental, endocrinology, gastroenterology, hematology, immunology, medical genetics, metabolism, nephrology, neurology, oncology, ophthalmology, orthopedics, and pulmonology. For 649 disorders, clinical area assignments were based on a previously published paper.[11] For all other gene-disorder pairs, one medical geneticist or medical student assigned the clinical area (T.M., S.B.), and another medical geneticist or genetic counseling student verified this assignment (S.A., S.B., N.B.G.).

Prevalence estimates for gene-disease pairs were obtained from four sources: Orphanet (https://www.orpha.net/), RX-genes (https://www.rx-genes.com/), and two previously published studies.[11,32] Gene-disorder links in Orphanet were established through the Orphacode, and only global prevalence estimates were retained. Only prevalence estimates

that could be linked to a single gene were withheld. Consolidated prevalence estimates were selected based on the following ordering: RX-genes, Orphanet, Kingsmore *et al* (2022)[32], and Gold *et al* (2023).[11] Prevalence data were obtained from these sources for 1,332 gene-disease pairs, covering 30% of the 4,390 genes. Notably, 77.33% of the genes which could be linked to a unique disorder for which a prevalence estimate could be found, had a prevalence of 1 per 1,000,000 or less, highlighting the ultra-rare nature of many disorders included in newborn sequencing programs.

Additional gene and disorder characteristics, including disease penetrance, severity, treatment acceptability and efficacy, age of onset, evidence base (which refers to the level of knowledge about the natural history of the disorder and its treatments), inheritance patterns and the existence of an orthogonal confirmatory non-diagnostic test, were derived from five previously published studies.[2,11,51,52] When two modes of inheritance were implicated for the same gene and disease in these studies, such as for *MYO6*, a cause of non-syndromic deafness, dominant inheritance was selected as it was expected to lead to the most inclusive reporting criteria.

Gene-disorder pairs were also matched with ClinGen (https://clinicalgenome.org/) gene-disease curations, which were evaluated using a standardized approach to assess the strength of evidence linking a gene to a monogenic disease. Additionally, ClinGen clinical pediatric and adult actionability curations were obtained, with the highest actionability score retained when multiple curations were available.[8,52] For gene-disorder pairs with both pediatric and adult curations, only the pediatric score was retained.

Three existing metrics that address the suitability of genes for newborn sequencing were also included. The age-based semi-quantitative metric (ASQM) score[51,52] is a metric which assigns a number between 0 and 15 to a gene-disease pair to denote overall appropriateness for newborn screening based on several sub-scores. The BabySeq

Category is another metric scored by the BabySeq Project,[2] where BabySeq Category A is designated as the category of genes most amenable to newborn screening, while Category C is considered less amenable to newborn screening. Finally, we incorporated the proportion of 238 rare disease experts who recommended screening newborns for 649 genes, as determined by an online survey.[11]

Additional information on the statistical analyses

All statistical analyses were carried out in Stata 18 (College Station, TX), R version 4.3.1 (Vienna, Austria) and Python version 3.11.2 (Python Software Foundation, Beaverton, OR). Jaccard similarity indices were calculated to provide information on the concordance across all lists of genes (Figure 2C and Supplementary Figure 4). The Jaccard index measures the number of genes in the intersection set divided by the number of genes in the union set of two gene lists. The UpSet plot was plotted using the UpSet[68] library in R (Figure 2D).

Regression coefficients on each characteristic were measured in a separate regression, where the only other control was the RUSP category (Figure 3A, Supplementary Table 5). Regression coefficients were also obtained for each program separately running several regressions for each program, one for each program-characteristic combination, while also controlling for RUSP category (Figure 3B, Supplementary Table 7). Several multivariate regression models were evaluated (Supplementary Table 6). Among them, specification (5), which included the most comprehensive set of independent variables, was used to estimate the effect of the change in a gene characteristic on overall gene list inclusion. However, it is important to note that this analysis identifies associations rather than causal relationships, even with the inclusion of additional controls.

The distribution of genes across several quantitative scores previously designed to assess the overall usefulness of disorders for NBSeq, including the BabySeq Category[2] and ASQM

Score[51,52] were calculated within each program (Supplementary Table 4), and correlations with overall gene inclusion across NBSeq programs was plotted (Supplementary Figure 6).

Additional information on the machine learning model

The prediction analysis was implemented in R using linear regression, random forest and boosted trees (glm, randomforest and gbm packages). Our machine learning algorithm was developed to predict a binary variable: whether a gene was included in an NBSeq program's gene list. We also experimented using the proportion of 27 NBSeq programs that included the gene as an outcome measure, but results were similar. Since the BabySeq project uses an "elective exome approach" that includes nearly all genes associated with human disease, we excluded this list when training the model. The overall dataset used for prediction consisted of 114,140 program-gene observations. We randomly assigned 80% of genes (91,312 observations) to the training set, and 20% to the hold-out test set.

For the 13 gene and disease characteristics included in the model, missing values were handled by adding dummy variables in the regression model and setting the missing predictor to zero. In the random forest and boosted trees models, missing values were set to -1 or labeled as 'missing' in the case of categorical variables.

We conducted a grid search using cross-validation to optimize the hyperparameters in the boosted trees model using the caret package. We optimized interaction depth (interaction.depth: 1, 5), number of trees (n.trees: 100, 500), learning rate (shrinkage: 0.01, 0.1), and minimum observations per node (n.minobsinnode: 10, 20). The final model configuration was chosen based on its performance during three-fold cross-validation, aiming to maximize predictive accuracy.

The performance of each model was evaluated using Receiver Operating Characteristic (ROC) curves and the Area Under the Curve (AUC) metric (Figure 3C). We plotted

distribution plots, showing the distribution of predictions for all models (Figure 3C, Supplementary Figure 7). Additionally, we plotted a calibration plot, showing the observed versus predicted inclusion probabilities for each gene-disorder pair in the test set (Supplementary Figure 7). We assessed the importance of gene and disease characteristics in the boosted trees model using the gbm package, where importance was measured by the mean decrease in accuracy for random forest and reduction in deviance for boosted trees (Supplementary Figure 8).

Acknowledgements

This work was supported by the following grants: T32GM007748 (S.B.), R01HG011773 (N.G.), K08HG012811-01 (N.B.G.), TR003201 (N.B.G.), HD077671 (R.C.G.) TR003201 (R.C.G.), and EU-IMI H2020 GRANT 101034427 (A.F., J.K.).

Ethics declaration

This study did not involve experiments on human participants or animals. All outcome data utilized in this research were aggregated and obtained from previously published sources, which are cited within the manuscript. As no individualized or patient-specific data were used, Institutional Review Board (IRB) or Research Ethics Committee (REC) approval were not required.

Competing interests

L.M.A., A.J.C. and R.J.T. are employees and shareholders at Illumina Inc. N.G. is co-founder and equity owner of Datavisyn. N.B.G. provides occasional consulting services to RCG Consulting and receives honoraria from Ambry Genetics. R.C.G. has received compensation for advising the following companies: Allelica, Atria, Fabric, Genomic Life and Juniper Genomics; and is co-founder of Genome Medical and Nurture Genomics. B.E.R. and K.L.S. are consultants at Nurture Genomics. L.S. received personal compensation from Zentech and Illumina Inc. P.T. is a co-founder of PlumCare RWE, LLC.

Author contributions

Conceptualization: L.M.A., D.B., F.B., A.J.C., N.E., A.F., N.B.G., R.C.G., J.K., T.M., B.E.R., K.L.S., L.S., R.J.T. Data curation: S.B., A.J.C., T.M., K.L.S, H.Z. Formal analysis: N.B.G., T.M. Funding acquisition: R.C.G, L.S., P.T. Investigation: S.A., S.B., N.B.G., T.M. Methodology: N.G., N.B.G., R.C.G., T.M. Resources: H.Z. Project administration: T.M. Software: T.M. Supervision: N.B.G., R.C.G., L.S. Visualization: N.G., N.B.G., T.M. Writing-original draft: S.A., N.B.G., T.M. Writing-review & editing: all authors.

Data and materials availability

All datasets generated and/or analyzed in this study, along with the Stata, R, and Python code necessary to replicate the results, are available at https://github.com/tjminten/gim_genelist.

Web resources

BabyDetect, https://babydetect.com/en/
BabyScreen+, https://babyscreen.mcri.edu.au/
BabySeq, https://www.genomes2people.org/research/babyseq/
BeginNGS, https://radygenomics.org/begin-ngs-newborn-sequencing/
Early Check, https://earlycheck.org/
FirstSteps, https://www.firststeps-ngs.gr/
FORESITE 360, https://foresite360.com/
Fulgent Genetics, https://www.fulgentgenetics.com/
Genomics England Newborn Genomes Programme, https://www.genomicsengland.co.uk/initiatives/newborns
GUARDIAN Study, https://guardian-study.org/
International Consortium on Newborn Sequencing (ICoNS), https://www.iconseq.org/
Igenomix, https://www.igenomix.eu/
Kenya Bioinformatics Institute, https://www.kibs.co.ke/
Mendelics, https://mendelics.com.br/
NEW_LIVES, https://www.klinikum.uni-heidelberg.de/en/new-lives-genomic-newborn-screening-programs
NewbornsInSA, https://www.wch.sa.gov.au/research/other-research-projects/newbornsinsa-research-study
Nurture Genomics, https://nurturegenomics.com/
Screen4Care, https://screen4care.eu/
ScreenPlus, https://www.einsteinmed.edu/research/screenplus/
PerkinElmer (now Revvity), https://www.revvity.com/be-en/category/newborn-screening

Supplement A: ICoNS Gene List Contributors

Programs:

BabyDetect, BabyScreen+, BabySeq, BeginNGS, Chen et al. 2023, Early Check, FirstSteps, the Generation study, gnSTAR, GUARDIAN study, Jian et al. 2022, Lee et al. 2019, Luo et al. 2020, NeoExome, NeoSeq, NESTS, NewbornsInSA, Screen4Care, Progetto Genoma Puglia, Wang et al. 2023, FORESITE 360, Fulgent, Igenomix, Nurture Genomics, PerkinElmer (now Revvity), Sema4.

Individuals:

First name and initials	**Last name**	**Degrees**	**Affiliation**	**Program**
Mattia	Gentile			Progetto Genoma Puglia
Paola	Orsini			Progetto Genoma Puglia
Romina	Ficarella			Progetto Genoma Puglia
Maria Luisa	Valente			Progetto Genoma Puglia
Emanuela	Ponzi			Progetto Genoma Puglia
Athina	Ververi	MD, PhD, MSc. PgCert	Papageorgiou General Hospital, Thessaloniki, Greece	FirstSteps
Maria	Koutsogianni	MD, MSc.	Institute of Child Health Great Ormond Street University College London.	FirstSteps
Huang	Xinwen			gnSTAR
Xiao	Rui			gnSTAR
Zhao	Zhengyan			gnSTAR
Matthew J.	Pelo			FORESITE 360 by Fore Genomics

Jovanka	King	PhD FRACP FRCPA BMBS (Hons) BPod	Genetics and Molecular Pathology, SA Pathology, Adelaide SA 5000, Australia Adelaide Medical School, The University of Adelaide, Adelaide SA 5000, Australia The Women's and Children's Health Network, Adelaide SA 5000, Australia	NewbornsInSA
Carol	Siu	MBBS, PhD, FRCPA, FRCPath	Genetics and Molecular Pathology, SA Pathology, Adelaide SA 5000, Australia Adelaide Medical School, The University of Adelaide, Adelaide SA 5000, Australia	NewbornsInSA
Karin	Kassahn	PhD, FFSc(RCPA)	Genetics and Molecular Pathology, SA Pathology, Adelaide SA 5000, Australia Adelaide Medical School, The University of Adelaide, Adelaide SA 5000, Australia	NewbornsInSA
Sansen	Stefaan		Sanofi	Screen4Care
Enrico	Bertini		Paediatric Hospital Bambino Gesù Rome	Screen4Care
Aldona	Zygmunt		Pfizer	Screen4Care

Supplement B: International Consortium on Newborn Sequencing (ICoNS) authors

Sophia Adelson
Emanuele Agolini
Aljazi Al-Maraghi
Karla Alex
Fowzan Alkuraya
Ammira Alshabeeb Akil
Munira Alshehri
Derek Ansel
Niki Armstrong
Matthew Aujla
Don Bailey
Mei Baker
Jorune Balciuniene
Andrew Barry
Bruce Bennetts
Melissa Berenger
Jonathan Berg
Donna Bernstein
Arindam Bhatatcharjee
Sucheta Bhatt
David Bick
Tracey Bishop
Asaf Bitton
François Boemer
Natasha Bonhomme
George Bowley
Brenna Boyd
Heiko Brennenstuhl
Steven Brenner
Mairead Bresnahan
Thomas Brewster
PJ Brooks
Katya Broomberg
Amy Brower
Gemma Brown
James Buchanan
Caleb Bupp
Mattia Gentile
Jessica Giordano
Ulrich Glumer Jensen
David Godler
Nina Gold
Aaron Goldenberg
Katie GoldenGrant
Cassie Goldman
José Manuel González de Aledo-Castillo
Daniel Gottlieb
Robert Green
Christopher Greene
Brooke Greenstein
Scott Grosse
Annette Grueters
Gulcin Gumus
Kelly Hagman
Kevin Hall
Aymeric Harmant
Sally Hartmanis
Robin Hayeems
Rose Heald
Madhuri Hegde
Rebecca Heiner-Fokkema
Lidewij Henneman
Becca Hernan
Charlotte Hobbs
Ingrid Holm
Layla Horwitz
Zhanzhi Hu
Maria Iascone
Ken Irvine
Guanjun Jin
Kelsey Kalbfleisch
Ines Kander
Lucy Kaplun
Dalia Kasperaviciute
Mette Nyegaard
Justin O'Sullivan
Jelili Ojodu
Paola Orsini
Andrea Oza
Katrina Paleologos
Richard Parad
Holly Peay
Matthew Pelo
Carolyn Philstrom
Dominique Pichard
Amanda Pichini
Holly Pickering
Michelle Pirreca
Malgorzata Ponikowska
Amy Ponte
Andreas Posch
Cynthia Powell
Liana Protopsaltis
Yeyson Quevedo
Marianna Raia
Rebecca Reimers
Andy Rohrwasser
Paul Rollier
Lene Rottensten
Irakli Rtskhiladze
Nabihah Sachedina
George Sahyoun
Aditi Satija
Christian Schaaf
Jennifer Schleit
Richard Scott
Lauren Scully
Stacey Seeloff
Laurent Servais
Nidhi Shah
Maija Siitonen

Candance Cameron
Lauren Capacchione
Diana Carli
Onassis Castillo Ceballo
Kee Chan
Jillian Chance
Georgia Charalambidou
Winnie Chen
Yun-Ru Chen
Wendy Chung
Brian Chung
Megan Clarke
Susan Clasper
F. Sessions Cole
Heidi Cope
Stephanie Coury
Tony Cox
Tamara Dangouloff
Earnest James Paul Daniel
Katrin Eivindardottir Danielsen
Emeline Davoine
Tom Defay
Geethanjali Devadoss Gandhi
Joseph Dewulf
Lisa Diller
Pakhi Dixit
Martijn Dolle
Lilian Downie
Erin Drake
Suzanne Drury
Annelotte Duintjer
Bugrahan Duz
David Eckstein
Matthew Ellinwood
Katarzyna Ellsworth
Sarah Elsea
Nicolas Encina
Harriet Etheredge
Laurence Faivre
Karin Kassahn
Leni Kauko
Riina Kaukonen
Nicole Kelly
Dhayo Khangsar
Jovanka King
Clare Kingsley
Stephen Kingsmore
Brian Kirmse
Rachel Klein
Stefan Koelker
Youssef Kousa
Elizaveta Krupoderova
Paul Kruszka
Katherine Langley
Ciara Leckie
Emmanuelle Lecommandeur
David Ledbetter
Pamela Lee
Beomhee Lee
Camille Level
Celine Lewis
Anna Lewis
Ruby Liu
Mauro Longoni
Alberte Lundquist
Sebastian Lunke
Kate MacDuffie
Ankit Malhotra
Lionel Marcelis
Maria Martinez-Fresno
Gert Matthijs
Roberts Melbardis
Jessica Merritt
Radja Messai Badji
Lou Metherell
Nanna Balle Mikkelsen
Laura Milko
Nicole Miller
Sikha Singh
Carol Siu
Hadley Smith
Lisa Sniderman King
Neal Sondheimer
Lourdes St George
Zornitza Stark
Robert Steiner
Ulrik Stoltze
Asbjørg Stray-Pedersen
Kristen Sund
Paris Tafas
Polakit Teekakirikul
Dimitrios Thanos
Audrey Thurm
Meekai To
Petros Tsipouras
Alice Tuff-Lacey
Heather Turner
Philip Twiss
Fiona Ulph
Daniel Uribe
Tiina Urv
Cora Vacher
Kris Van Den Bogaert
Mirjam van der Burg
Eva Van Steijvoort
Yiota Veloudi
Elizabeth Vengoechea
Els Voorhoeve
Martin Vu
Melissa Wasserstein
Michael Watson
Bryn Webb
Anna Wedell
Thomas Westover
Alexandra Wiedemann
Meredith Wright
Cindy Wu

Alessandra Ferlini
Monica Ferrie
Terri Finkel
Petra Furu
Jamie Galarza-Cornejo
Ya Gao
Judit Garcia-Villoria
Liz Gardner
Amy Gaviglio
Michael Gelb
Thomas Minten
Sian Morgan
Katarzyna Mosiewicz
Ulrike Mütze
Sukhvinder Nicklen
Minna Niemela
Dau-Ming Niu
Sarah Norris
Antonio Novelli
Arwa Nusair
Julie Yeo
Nancy Yin-Hsiu Chien
Shamila Yusuff
Tomasz Zemojtel
Bethany Zettler
Zhengyan Zhao
Joanna Ziff
Rebekah Zimmerman
Michela Zuccolo

Supplementary Material

Contents

Supplementary Figure 1. Gene Inclusion Distribution
Supplementary Figure 2. Gene List Concordance
Supplementary Figure 3. Gene List Venn Diagrams
Supplementary Figure 4. Jaccard Heat Plots by Clinical Area
Supplementary Figure 5. Correlation of Gene List Inclusion and Different Categories
Supplementary Figure 6. Correlation of Gene List Inclusion and Previously Published Metrics
Supplementary Figure 7. Prediction Model Graphs
Supplementary Figure 8. Variable Importance in Boosted Trees Model

Supplementary Table 1. Research and Commercial Genomic Newborn Screening Programs
Supplementary Table 2. Inclusion Criteria Employed by Various Programs
Supplementary Table 3. Gene-Disease Characteristic Descriptions
Supplementary Table 4. Gene List Summary Statistics
Supplementary Table 5. Univariate Gene List Regressions Results
Supplementary Table 6. Multivariate Gene List Inclusion Regressions
Supplementary Table 7. Univariate Gene List Regression Results by Program

Supplementary Figure 1. Gene inclusion distribution



Notes: The distribution of gene list inclusion for all gene-disorder pairs included in any of the NBSeq programs (n=4,390).

Supplementary Figure 2. Gene list concordance



Notes: (A) A bar chart displaying the distribution of the number of programs that include genes from each program's gene list, highlighting the overall concordance within each list. (B) A gene map visualizing the presence of 4,390 genes across 27 NBSeq studies. On the x-axis, all 4,390 genes are listed, while the y-axis represents the 27 studies, and the RUSP. Each colored cell indicates that a gene is included in a given study's list. RUSP, Recommended Uniform Screening Panel.

Supplementary Figure 3. Gene list venn diagrams

Notes: Venn diagrams illustrating the overlap between gene lists from different studies. The size of each circle scales proportionally to reflect the number of genes in each study. Within each overlapping region, the numbers indicate the exact count of genes, with the corresponding percentages representing their proportion relative to the total combined gene count across all three studies.

Supplementary Figure 4. Jaccard heat plots by clinical area



Notes: Jaccard similarity indices for all pairs NBSeq programs, looking only at genes associated with (A) metabolic (n=492), (B) immunologic (n=274), (C) neurologic (n=1,251), and (D) endocrinologic disorders (n=352). This index measures the degree of overlap between gene lists by comparing the intersection and union of the sets (see Methods). The resulting indices offer a quantitative comparison of how closely related the gene lists are for these specific types of disorders.

Supplementary Figure 5. Correlation of gene list inclusion and different categories



Notes: Bar charts showing the distribution of gene list inclusion across different categories. The color-coded bars indicate the number of lists each gene is included in. (A) RUSP Core (n=48) and Secondary (n=39). BabySeq Category A (n=826), B (n=59), and C (n=452). NC Nexus Category 1 (n=467), 2 (n=241), 3 (n=19), 4 (n=14). RUSP, Recommended Uniform Screening Panel.

Supplementary Figure 6. Correlation of gene list inclusion and previously published metrics



Notes: (A) Box plot showing the distribution of expert recommendations for gene screening across concordance levels, based on Gold et al. (2023) (n=649). (B) Box plot of ASQM scores for genes, from Milko et al. (2019), across concordance levels (n=747). (C) Box plot of ClinGen pediatric actionability scores across concordance levels (n=135). Each plot displays the median (center line), interquartile range (box), and full range (whiskers) within each group. ASQM, Age-Based Semi Quantitative Metric.

Supplementary Figure 7. Prediction model graphs



Notes: (A) Scatter plots of the 20% hold-out test set, plotting predicted versus observed gene list inclusion. Perfect predictions would align along a 45-degree line. (B) Histogram displaying the distribution of predicted gene list inclusion for 4,390 genes.

Supplementary Figure 8. Variable importance in boosted trees model



Notes: Bar chart showing the relative importance of variables in the boosted trees model, measured by the reduction in deviance.

Supplementary Table 1. Research and commercial genomic newborn screening programs

	Project name	Country	Status (Aug 2024)	Sequencing type	Intended sample size	Unique gene names in list
Research studies	BabyDetect*	Belgium	Ongoing	Panel	40,000	405
	BabyScreen+*	Australia	Ongoing	GS/ES	1,000	605
	BabySeq*	Massachusetts, USA	Ongoing	GS	100,000	4,299
	BeginNGS*	California, USA	Ongoing	GS/ES	2,000	357
	Chen et al. 2023*	China	Completed	Panel	29,601	142
	Cradle	Netherlands	Expected			
	Early Check*	North Carolina, USA	Ongoing	GS/ES	10,000	169
	FirstSteps*	Greece	Ongoing	GS/ES	101,000	385
	Generation study*	England	Ongoing	GS	100,000	479
	gnSTAR*	China	Completed	Panel	4,986	134
	GUARDIAN study*	New York, USA	Ongoing	GS/ES	100,000	314
	Jian et al. 2022*	China	Completed	GS	321	251
	Lee et al. 2019*	South Korea	Completed	Panel	48	198
	Luo et al. 2020*	China	Completed	Panel	1,127	569
	NeoExome*	China	Completed	Panel	3,423	601
	NeoSeq*	China	Completed	Panel	196	135
	NESTS*	China	Completed	Panel	11,484	465
	New Lives	Germany	Expected			
	Newborn Genomics Prog	New Zealand	Expected			
	NewbornsInSA*	Australia	Expected	GS	1,000	613
	Perigenomed	France	Expected	GS	20,000	
	Progetto Genoma Puglia*	Italy	Expected	GS	6,000	404
	Screen4Care*	European Union	Expected	Panel	18,000	245
	ScreenPlus	New York, USA	Completed	Panel		
	Sidra Medicine	Qatar	Expected			
	TRAIL	Australia	Expected			
	Wang et al. 2023*	China	Completed	Panel	10,224	162
Commercial programs	FORESITE 360*	USA	Ongoing	GS		306
	Fulgent*	USA	Ongoing	Panel		255
	Igenomix*	Spain	Ongoing	Panel		237
	KIBs	Kenya	Ongoing	Panel		
	Mendelics*	Brazil	Ongoing	Panel		284
	Nurture Genomics*	USA	Ongoing	GS		412
	PerkinElmer*	USA	Ongoing	Panel		268
	Sema4*	USA	Completed	Panel		167

Notes: Information on various genomic newborn screening research studies and commercial programs. Gene lists from 27 of these programs were included in the analysis (program names denoted with an asterisk). GS, genome sequencing.

Supplementary Table 2. Inclusion criteria employed by various programs for selecting gene-disease associations for genomic newborn screening.

PROJECT	INCLUSION CRITERIA	SOURCE
BabyDetect	"General inclusion criteria for genes incorporated into the test panel were the following: significant life-expectancy consequences or severe disability associated with untreated patients, disease onset before 5 years of age, strong genotype-phenotype correlation, existence of a disease-modifying treatment accessible to the diagnosed patients, and significant benefit of prompt treatment. Genes with mutations that underlie diseases currently screened in our biochemical panel were also included even if they did not match these criteria (e.g., G6PD deficiency). Endorsement by pediatricians who specialized in treatment of the disease was mandatory. Screening for a given disease was discontinued if a disease-modifying treatment became unavailable or due to operational issues such as an unacceptable rate of false positives. Discussions were held with experts periodically to review the list of disorders and genes in the tNGS panel."	Boemer et al. 2025
BabyScreen+	"Genes included in the screening meet the following criteria: A. Screening can be performed with confidence using currently available technology B. The condition associated with the gene has a serious impact on health and/or is life-limiting C. The condition associated with the gene usually affects children under 5 years of age D. There is available treatment that prevents, cures or significantly reduces the severity of the condition"	https://babyscreen.mcri.edu.au/conditions-screened/
BabySeq	The BabySeq study uses a gene filtration and selection approach to generate a list of >6,000 genes disease associations present in ClinVar, HGMD or OMIM, which is then further filtered to approximately ~4,300 genes with stronger association to disease.	Lazo de la Vega et al. 2021
BeginNGS	"Two mandatory criteria 1. Severe, childhood-onset disease 2. Effective therapeutic intervention available"	Owen et al. 2022
Chen et al. 2023	"One of the following criteria A. Diseases in the current NBS program in China B. Diseases on the first national list of rare diseases in China C. Diseases on the list of major rare diseases in Shanghai (2016 Edition) D. Diseases in the NBS program recommended by the American College of Medical Genetics and Genomics E. Treatable inherited disorders with a high carrier frequency in Southeast Asia"	Chen et al. 2023
Early Check	"Panel 1 includes gene-condition pairs with high actionability and early age of action (age at intervention initiation), which makes them comparable to core conditions on the Recommended Uniform Screening Panel (RUSP), a set of conditions the Secretary of the U.S. Department of Health and Human Services (HHS) recommends for inclusion in all state NBS programs. All currently recommended RUSP conditions for which sequencing is informative were automatically included on Early Check Panel 1, and other non-RUSP conditions were evaluated for the panel."	Cope et al. 2024
FirstSteps	"The purpose of FirstSteps is the early detection of potentially treatable diseases, so that they can be treated immediately and their complications can be prevented or minimized. The goal of FirstSteps is to ensure prompt and valid treatment for asymptomatic newborns suffering from genetic diseases, in order to prevent or minimize the complications of the disease."	https://www.firststeps-ngs.gr/, translated from Greek
Generation study	"Four mandatory criteria 1. There is strong evidence that the genetic variant(s) causes the condition and can be reliably detected 2. A high proportion of individuals who have the genetic variant(s) would be expected to have symptoms that would have a debilitating impact on quality of life if left undiagnosed 3. Early or pre-symptomatic intervention for the condition has been shown to lead to substantially improved outcomes in children, compared to intervention after the onset of symptoms 4. Conditions screened for are only those for which the interventions are equitably accessible for all."	https://www.genomicsengland.co.uk/initiatives/newborns/choosing-conditions
gnSTAR	"Seventy four inborn disorders were included in this panel based on the Secretary's Advisory Committee on Heritable Disorders in Newborns and Children and the Wilson and Jungner criteria, disorders that can be detected by	Huang et al. 2022

	biochemical test were selected with consideration of Recommended Uniform Screening Panel (RUSP) recommendation, and disease with high incidences but cannot be screened by C-NBS in China were also enrolled.”	
GUARDIAN study	Genes associated with conditions with penetrance >90% before age 5 years and/or for which presymptomatic treatment would be recommended before age 5 years.	Ziegler et al. 2024
Jian et al. 2022	“Genes associated with 59 Mendelian disorders, 164 primary immunodeficiency diseases (PIDs) and five pharmacogenetic (PGx) genes, following the guidelines by the Recommended Uniform Screening Panel (RUSP), the International Union of Immunologic Societies (IUIS) Expert Committee for PrimaryImmunodeficiency, the Dutch Pharmacogenetics Working Group (DPWG), and the Clinical Pharmacogenetics Implementation Consortium (CPIC).”	Jian et al. 2022
Lee et al. 2019	“Actionable child-onset-genes related to NBS was designed for diagnosis of a rare genetic disorder with low incidence before clinical symptoms occurred.”	Lee et al. 2019
NeoExome	“To design the NBS NGS panel covering monogenic diseases that are severe, actionable, and early onset for the Chinese population, we combined the following categorization of diseases in our study: 1) 248 related genes (249 diseases) that were included in China National Catalog of Rare Diseases. This catalog includes diseases with low incidence, high risk, and strong treatability based on the clinical data; 2) 360 genes (312 diseases) that were included in Preventable and Treatable Rare Diseases in China; 3) 79 genes (71 diseases) that were now in the conventional MS/MS NBS project in China; 4) 71 genes (71 diseases) that were included in the conventional NBS in China; 5) 149 genes (148 diseases) that were recommended by ACMG; 6) 55 genes (57 diseases) that were recommended by the experts of the Chinese NBS Laboratory Committee. Moreover, a list of diseases with high prevalence in the Chinese population based on the database about positive monogenetic diseases in 40000 ill newborns by MyGenostics was also included. This list included 141 diseases and 94 related genes.”	
NESTS	“After curation, we selected 465 causative genes for 596 early-onset, relatively high incidence, and potentially actionable severe inherited diseases in our initiative panel.”	Hao et al. 2022
NewbornsInSA	“The 600+ genetic conditions which we will look for meet these criteria: A. Condition occurs in childhood B. The condition is serious, and is expected to have symptoms that would have a debilitating impact on quality of life if undiagnosed C. There is an effective treatment or management option available D. There is strong evidence that the genetic variant causes the condition E. Our laboratory can reliably detect the condition.”	https://www.wch.sa.gov.au/research/newbornsinsa-research-study
Progetto Genoma Puglia	Genes selected according to age of early onset, significant mortality/morbidty, available treatments and proven effectiveness of early diagnosis in the best/correct care pathway.	ICoNS 2024
Screen4Care	Five inclusion criteria, including treatability, disease onset, disease severity, penetrance, clinical validity.	Internal document
FORESITE 360	The test targets detectable genetic alterations associated with treatable childhood-onset conditions.	https://www.foregenomics.com/products/pediatric-genetic-health-screen
Fulgent	Genetic test that identifies DNA changes that can cause infants to develop severe or life-altering conditions. Screen for these conditions, where early detection, intervention, and management are essential for the infant's overall health and quality of life.	https://www.fulgentgenetics.com/products/newborn/newborn.html
Igenomix	These genes are responsible for developmental, genetic and metabolic disorders that cause serious health problems starting in early childhood. The ultimate benefit is an early intervention to prevent intellectual and physical disabilities as well as life-threatening illnesses.	https://www.igenomix.eu/genomics-precision-diagnostic/newborn-screening/
Nurture Genomics	Actionable, childhood-onset conditions, considering: • Are most reported cases very early childhood-onset? • Is the natural history of the disease known? • Does early diagnosis result in better outcomes? • Does a treatment or management of the condition exist?	https://nurturegenomics.com/

	• Is the condition able to be further characterized using non-genetic (orthogonal) testing?	
PerkinElmer	268 nuclear genes curated for association with medically actionable childhood-onset conditions.	Balciuniene et al. 2023
Sema4	"Conditions that have onset in infancy or early childhood and for which there is treatment or medical management that, when administered early in an infant or child's life, will significantly improve the clinical outcome. Conditions included in this panel were curated based on criteria such as: inclusion on current state mandated newborn screening panels, onset of symptoms occurring <10 years of age, evidence of high penetrance (>80%), and availability of a treatment or improvement in life due to early intervention."	Sema4 Natalis Action Sheet

Notes: The criteria enclosed in quotation marks ("") were directly copied from the specified source material to ensure accuracy and preserve the original wording as presented by the authors.

Supplementary Table 3. Gene-disease characteristic descriptions

Dataset	Number of matched gene-disease pairs	Characteristic	Values	Description	Source
ASQM	747	ASQM score	0-15	Total score of ratings on severity, likelihood, efficacy, acceptability and knowledge	Milko et al. 2019; DeCristo et al. 2021
		NC Nexus category	1	Pediatric conditions with high actionability	
			2	Pediatric conditions with low or no actionability	
			3	Adult conditions with high actionability	
			4	Adult conditions with low or no actionability	
		Severity	0-3, recoded to 0-1	Rating to question "What is the effect on morbidity or mortality to an individual carrying a pathogenic variant in this gene?"	
		Likelihood	0-3, recoded to 0-1	Rating to question "What is the chance that a threat will materialize?"	
		Efficacy	0-3, recoded to 0-1	Rating to question "How effective are interventions for preventing the harm?"	
		Acceptability	0-3, recoded to 0-1	Rating to question "How acceptable are the interventions in terms of the burdens or risks placed on the individual?"	
		Knowledge	0-3, recoded to 0-1	Rating to question "What is the evidence base for decisions about the natural history of the disease, and interventions used for preventing serious outcomes?"	
		Inheritance	Autosomal dominant, recessive, x-linked, or other		
		Age of Onset	Adolescent/adult	Disease presents at age 11 and beyond	
			Childhood	Disease presents at age 2 to 10	
			Infant/neonatal	Disease presents between birth and age 2	
			Birth	Disease presents at birth	
BabySeq	1,390	BabySeq category	A	Genes included in the newborn genomic sequencing report with definitive or strong evidence to cause a highly penetrant childhood-onset disorder	Ceyhan et al. 2017
			B	Genes included in the newborn genomic sequencing report based on actionability during childhood	
			C	Genes that did not meet criteria to be returned in the newborn genomic sequencing report	
		Evidence	Conflicting, limited, moderate, strong, definitive, or no evidence	Evidence that the gene has a causal role in disease	
		Penetrance	High	≥80% of individuals were symptomatic	
			Moderate	20–80% of individuals were symptomatic	
			Low	<20% of individuals were symptomatic	
		Inheritance	Autosomal dominant, autosomal recessive, autosomal recessive digene, complex inheritance, imprinting, mitochondrial inheritance, unknown inheritance, x-linked dominant, x-linked recessive		
Gold et al. 2023	649	Recommendation fraction	Fraction	Fraction of rare disease experts that responds yes to the question "Would you recommend screening for this gene?"	Gold et al. 2023
		Existence of orthogonal test	Yes, no	Existence of an orthogonal test	
ClinGen	1,000	Gene-disease validity	Definitive, disputed, limited, moderate, no known relationship, refuted, strong		Clinicalgenome.org
	135 (pediatric actionability) & 107 (adult actionability)	Level of evidence (for likelihood and effectiveness treatment)	ABCDN	A = substantial evidence, B = moderate evidence, C = minimal evidence, D = poor or conflicting evidence, N = non-systematically identified or expert contributed evidence	
		Severity	0-3	3 = sudden death, 2 = possible death or major morbidity, 1 = modest morbidity, 0 = minimal or no morbidity	
		Likelihood	0-3, ABCDN	3 = 40% chance, 2 = 5-39% chance, 1 = 1-4% chance, 0 = <1% chance or unknown	
		Nature of intervention	0-3	3 = low risk/medically acceptable/low intensity intervention, 2 = moderately acceptable/risk/intensive interventions, 1 = greater risk/less acceptable/substantial interventions, 0 = high risk/poor acceptable/intensive or no intervention	
		Effectiveness of treatment	0-3, ABCDN	3 = highly effective, 2 = moderately effective, 1 = minimally effective, 0 = ineffective/no intervention	
		Overall actionability score	0-12, ABCDN ABCDN		
Constructed in this paper	1,364	Prevalence	Disease frequency per 100,000	See methods for construction of this variable	RX-Genes, Orphanet, Gold et al. 2023, and Kingsmore et al. 2022
	4,474	Clinical area	cardiovascular, dermatology, ent/dental, endocrinology, gastroenterology, hematology, immunology, medical genetics, metabolism, nephrology, neurology, oncology, ophthalmology, orthopedics, and pulmonology	most relevant clinical area that would treat a diagnosed child	Gold et al. 2023 and own classifications
	4,474	RUSP disease association	Core, secondary, none	See methods for construction of this variable	Hrsa.gov

Notes: Each characteristic is detailed with its values, descriptions, and sources, providing context for the data used in the analysis. ASQM, Age-Based Semi Quantitative Metric.

Supplementary Table 4. Gene list summary statistics

	Genes included in at least one gene list	Average across pilots	BabyDetect	BabyScreen+	BabySeq2	BeginNGS	Chen et al.	Early Check	FirstSteps	FORESIT E 360	Fulgent	Generation	gnSTAR	GUARDIAN
All genes	4390	476	405	605	4299	357	142	169	385	306	255	479	134	314
Clinical area														
Cardiovascular	248	22	20	18	243	11	1	4	11	34	8	18	0	6
Dermatology	104	5	0	2	103	0	0	0	0	1	0	0	0	0
ENT/Dental	146	19	1	54	142	0	0	33	0	15	16	1	2	2
Endocrinology	352	53	44	105	348	42	15	22	43	40	38	90	14	29
Gastroenterology	77	10	13	16	75	4	4	4	4	7	6	19	4	6
Hematology	195	34	55	55	183	54	8	8	58	13	8	44	3	15
Immunology	274	57	64	122	250	69	12	10	70	26	26	106	11	96
Medical Genetics	556	32	7	21	546	7	1	5	7	12	11	9	4	1
Metabolism	492	121	129	138	480	108	87	67	119	99	98	89	90	119
Nephrology	122	15	9	17	120	11	4	7	14	10	10	17	0	11
Neurology	1251	74	51	36	1242	47	8	5	54	20	18	37	3	23
Oncology	126	10	2	16	122	1	1	2	1	23	11	14	2	2
Ophthalmology	259	13	8	2	258	0	0	0	1	4	3	1	0	2
Orthopedics	119	6	0	2	119	1	0	0	1	1	1	0	1	1
Pulmonology	67	6	2	1	66	2	1	2	2	1	1	34	0	1
RUSP														
Core	48	41	46	45	48	43	35	40	42	44	44	46	38	46
Secondary	39	27	33	24	38	28	21	14	27	27	25	18	28	30
ASQM														
Genes	741		240	340	732	194	114	168	211	269	225	255	112	194
Average ASQM score	10.30		11.15	11.52	10.32	11.49	11.57	12.42	11.41	11.62	11.68	11.50	11.62	11.30
BabySeq														
Genes	1337		253	365	1328	230	130	151	253	263	221	281	116	205
Genes in 3 categories														
A	826		204	300	826	172	120	135	192	217	204	228	104	179
B	59		11	8	59	11	3	7	11	29	5	5	5	7
C	452		38	57	443	47	7	9	50	17	12	48	7	19
Gold et al. 2023														
Genes	644		257	388	622	274	74	65	305	139	122	317	50	214
Avg recommendation	56.24		63	61	56	60	71	73	61	67	68	60	71	63

Table continues on next page.

	Igenomix	Jian et al.	Lee et al.	Luo et al.	Mendelics	NeoExome	NeoSeq	NESTS	NewbornsInSA	Nurture	PerkinElmer	Prog. Puglia	Screen4Care	Sema4	Wang et al.
All genes	237	251	198	569	284	601	135	465	613	412	268	404	245	167	162
Clinical area															
Cardiovascular	2	11	12	31	7	50	0	23	21	14	18	11	4	3	1
Dermatology	0	1	0	8	0	7	0	6	2	0	0	0	0	0	0
ENT/Dental	12	8	3	41	2	6	2	84	54	1	15	3	0	0	10
Endocrinology	37	8	23	41	47	73	14	23	106	53	38	52	33	27	14
Gastroenterology	6	2	3	10	17	17	4	5	16	10	7	6	1	6	4
Hematology	6	6	5	54	15	58	3	28	56	65	7	54	36	8	8
Immunology	24	118	4	34	52	40	11	30	122	77	26	73	28	13	12
Medical Genetics	1	17	21	58	0	39	4	37	21	6	13	5	2	1	3
Metabolism	126	66	81	142	107	169	91	87	139	135	99	138	96	86	90
Nephrology	6	0	7	15	11	25	0	34	18	17	10	10	6	8	4
Neurology	14	6	23	96	23	83	3	40	36	22	16	45	33	12	13
Oncology	0	5	2	9	1	12	2	4	16	9	14	5	2	2	1
Ophthalmology	1	1	9	15	1	14	0	32	3	1	3	1	1	0	0
Orthopedics	1	1	2	9	0	5	1	4	2	0	1	0	2	0	1
Pulmonology	1	1	3	6	1	3	0	28	1	2	1	1	1	1	1
RUSP															
Core	43	45	27	44	33	44	38	33	45	39	41	44	39	44	35
Secondary	34	34	20	33	21	38	29	29	24	20	25	37	25	27	21
ASQM															
Genes	196	136	126	316	168	301	113	277	346	235	236	242	176	167	125
Average ASQM score	11.26	11.12	11.23	10.96	11.54	10.82	11.59	11.09	11.51	11.23	11.67	11.32	11.94	11.69	11.66
BabySeq															
Genes	190	129	168	462	177	415	117	364	372	256	233	268	216	142	142
Genes in 3 categories															
A	166	106	139	385	155	312	104	278	304	209	204	215	189	129	130
B	5	5	10	19	3	29	5	15	10	10	16	10	6	4	3
C	19	18	19	58	19	74	8	71	58	37	13	43	21	9	9
Gold et al. 2023															
Genes	111	88	57	169	183	233	50	119	393	347	125	313	161	85	79
Avg recommendation	70	57	67	65	65	61	71	62	61	65	68	64	67	70	70

Notes: The upper part of the table shows the number of genes by clinical area. The ASQM, BabySeq, and Gold et al. 2023 sections display the number of genes each program has in common with these datasets, along with summary statistics. Averages are calculated as means. The RUSP category indicates whether genes are in the Core or Secondary panel. ASQM, Age-Based Semi Quantitative Metric; RUSP, Recommended Uniform Screening Panel.

Supplementary Table 5. Univariate gene list regressions results

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Dependent variable: gene list inclusion fraction								
RUSP (base: not in RUSP)									
Core	0.747***	0.521***	0.576***	0.608***	0.590***	0.606***	0.546***	0.330***	0.292***
	(0.019)	(0.032)	(0.034)	(0.033)	(0.033)	(0.033)	(0.031)	(0.065)	(0.058)
Secondary	0.600***	0.367***	0.452***	0.461***	0.464***	0.463***	0.451***	0.271***	0.320***
	(0.022)	(0.035)	(0.037)	(0.037)	(0.036)	(0.037)	(0.034)	(0.102)	(0.092)
Gene-disease characteristics									
Neonatal or infant onset		0.152***							
		(0.023)							
Severity			0.145***						
			(0.032)						
Penetrance				0.155***					
				(0.029)					
Efficacy					0.170***				
					(0.024)				
Acceptability						0.150***			
						(0.023)			
Evidence base							0.295***		
							(0.025)		
Existence of an orthogonal test								0.138***	
								(0.023)	
Expert recommendations									
≥80% Yes									0.435***
									(0.031)
Constant	0.093***	0.209***	0.168***	0.109***	0.133***	0.133***	0.077***	0.184***	0.273***
	(0.002)	(0.019)	(0.019)	(0.026)	(0.018)	(0.020)	(0.016)	(0.021)	(0.007)
Observations	4,475	747	749	749	749	749	749	637	649
R-squared	0.333	0.473	0.394	0.401	0.418	0.410	0.478	0.105	0.278

Standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1

Notes: Coefficients and standard errors (in parentheses) from univariate linear regressions, with the dependent variable being the gene list inclusion fraction (proportion of programs including each gene, between 0 and 1).

Supplementary Table 6. Multivariate gene list inclusion regressions

	(1)	(2)	(3)	(4)	(5)
RUSP (base: not in RUSP)					
Core	0.747***	0.274***	0.730***	0.405***	0.239***
	(0.019)	(0.057)	(0.029)	(0.029)	(0.078)
Secondary	0.600***	0.299***	0.552***	0.371***	0.044
	(0.022)	(0.090)	(0.033)	(0.031)	(0.085)
Expert recommendation					
≥80% Yes		0.418***			0.235***
		(0.030)			(0.034)
Penetrance (base: low or unknown)					
High			0.132***		0.192***
			(0.013)		(0.060)
Moderate			0.082***		0.123*
			(0.021)		(0.067)
Gene-disease characteristics					
Severity				0.135***	0.153**
				(0.029)	(0.059)
Penetrance				0.021	-0.020
				(0.026)	(0.086)
Efficacy				0.069**	0.097**
				(0.030)	(0.049)
Acceptability				0.138***	0.121**
				(0.030)	(0.054)
Evidence base				0.238***	0.148***
				(0.024)	(0.051)
Existence of orthogonal test		0.114***			0.147***
		(0.020)			(0.040)
Inheritance (base: other)					
AD				-0.037	-0.074
				(0.036)	(0.062)
AR				0.057	-0.004
				(0.035)	(0.062)
X-linked				0.109**	-0.011
				(0.044)	(0.068)
Age of onset (base: variable)					
Adolescent/adult				-0.062**	-0.182***
				(0.025)	(0.052)
Birth				-0.036	-0.007
				(0.024)	(0.051)
Childhood				0.014	-0.091**
				(0.025)	(0.043)
Neonatal or infant				0.111***	0.032
				(0.021)	(0.036)
Constant	0.093***	0.180***	0.058***	-0.175***	-0.180
	(0.002)	(0.018)	(0.012)	(0.048)	(0.130)
Observations	4,475	637	1,390	747	181
R-squared	0.333	0.314	0.429	0.622	0.662

Standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1

Notes: Coefficients and standard errors (in parentheses) from univariate linear regressions, with the dependent variable being the gene list inclusion fraction (proportion of programs including each gene, between 0 and 1). RUSP, Recommended Uniform Screening Panel. AD, autosomal dominant. AR, autosomal recessive.

Supplementary Table 7. Univariate gene list regression results by program

	BabyDetect	3abyScreen+	BabySeq2	BeginNGS	Chen et al.	Early Check	FirstSteps	Generation	gnSTAR	GUARDIAN	Jian et al.	Lee et al.	Luo et al.	NeoExome	NeoSeq
Gene-disease characteristics															
Neonatal or infant onset	0.241***	0.354***	0.002	0.209***	0.041	0.185***	0.199***	0.335***	0.114***	0.182***	0.105***	-0.016	0.064	0.022	0.115***
	(0.043)	(0.050)	(0.017)	(0.041)	(0.034)	(0.042)	(0.044)	(0.046)	(0.031)	(0.040)	(0.031)	(0.039)	(0.051)	(0.049)	(0.031)
Severity	0.265***	0.199***	0.044**	0.222***	0.077*	0.089	0.226***	0.132**	0.076*	0.235***	0.120***	0.061	0.039	0.291***	0.079*
	(0.059)	(0.069)	(0.022)	(0.056)	(0.045)	(0.056)	(0.059)	(0.064)	(0.041)	(0.054)	(0.041)	(0.051)	(0.067)	(0.064)	(0.041)
Penetrance	0.112**	0.261***	0.042**	0.188***	0.071*	0.239***	0.222***	0.205***	0.078**	0.121**	-0.009	0.042	0.227***	0.157***	0.065*
	(0.053)	(0.061)	(0.019)	(0.050)	(0.040)	(0.049)	(0.052)	(0.057)	(0.036)	(0.049)	(0.037)	(0.045)	(0.060)	(0.058)	(0.036)
Efficacy	0.167***	0.489***	0.014	0.137***	0.038	0.382***	0.111**	0.346***	0.071**	0.149***	0.091***	0.006	0.015	-0.049	0.076**
	(0.045)	(0.049)	(0.016)	(0.042)	(0.034)	(0.040)	(0.045)	(0.047)	(0.031)	(0.041)	(0.031)	(0.038)	(0.051)	(0.049)	(0.031)
Acceptability	0.134***	0.376***	0.003	0.178***	0.053	0.295***	0.166***	0.219***	0.056*	0.062	0.035	0.079**	0.068	-0.056	0.059**
	(0.044)	(0.050)	(0.016)	(0.041)	(0.033)	(0.040)	(0.043)	(0.047)	(0.030)	(0.041)	(0.030)	(0.038)	(0.050)	(0.048)	(0.030)
Evidemce base	0.140***	0.411***	0.095***	0.195***	0.261***	0.373***	0.241***	0.275***	0.216***	0.176***	0.055	0.251***	0.538***	0.417***	0.212***
	(0.049)	(0.055)	(0.017)	(0.046)	(0.036)	(0.044)	(0.048)	(0.052)	(0.033)	(0.045)	(0.034)	(0.041)	(0.052)	(0.052)	(0.033)
Existence of an orthogonal test	0.338***	0.256***	-0.027	0.189***	0.069**	0.085***	0.222***	0.279***	0.061**	0.244***	0.033	-0.012	0.113**	0.106**	0.061**
	(0.052)	(0.053)	(0.022)	(0.054)	(0.035)	(0.033)	(0.055)	(0.054)	(0.029)	(0.051)	(0.037)	(0.031)	(0.048)	(0.053)	(0.029)
Expert recommendations	0.511***	0.331***	0.043	0.187**	0.526***	0.468***	0.358***	0.271***	0.412***	0.464***	-0.136**	0.333***	0.442***	0.509***	0.412***
≥80% Yes	(0.079)	(0.081)	(0.034)	(0.082)	(0.049)	(0.046)	(0.082)	(0.083)	(0.041)	(0.076)	(0.055)	(0.044)	(0.071)	(0.078)	(0.041)

Table continues on next page.

	NESTS	NewbornsInSA	Prog. Puglia	Screen4Care	Wang et al.	FORESITE 360	Fulgent	Igenomix	Mendelics	Nurture	PerkinElmer	Sema4
Gene-disease characteristics												
Neonatal or infant onset	0.021	0.333***	0.198***	0.221***	0.050	0.015	0.228***	0.173***	0.228***	0.167***	0.142***	0.182***
	(0.050)	(0.051)	(0.044)	(0.041)	(0.037)	(0.049)	(0.045)	(0.041)	(0.042)	(0.047)	(0.047)	(0.038)
Severity	-0.312***	0.216***	0.267***	0.235***	0.045	0.286***	0.171***	0.109**	0.154***	0.197***	0.245***	0.142***
	(0.067)	(0.069)	(0.059)	(0.055)	(0.048)	(0.064)	(0.061)	(0.055)	(0.056)	(0.064)	(0.062)	(0.051)
Penetrance	0.221***	0.268***	0.198***	0.204***	0.093**	0.154***	0.191***	0.153***	0.143***	0.230***	0.181***	0.115**
	(0.060)	(0.061)	(0.053)	(0.049)	(0.043)	(0.058)	(0.054)	(0.049)	(0.050)	(0.057)	(0.056)	(0.046)
Efficacy	0.285***	0.485***	0.145***	0.214***	0.066*	0.266***	0.230***	0.097**	0.192***	0.141***	0.239***	0.188***
	(0.050)	(0.050)	(0.045)	(0.041)	(0.036)	(0.048)	(0.045)	(0.041)	(0.042)	(0.048)	(0.047)	(0.038)
Acceptability	0.278***	0.375***	0.174***	0.159***	0.085**	0.272***	0.227***	0.080**	0.143***	0.142***	0.230***	0.167***
	(0.049)	(0.050)	(0.044)	(0.041)	(0.035)	(0.047)	(0.044)	(0.041)	(0.042)	(0.047)	(0.046)	(0.038)
Evidemce base	0.314***	0.434***	0.273***	0.397***	0.315***	0.539***	0.440***	0.283***	0.205***	0.194***	0.479***	0.240***
	(0.055)	(0.055)	(0.049)	(0.044)	(0.038)	(0.050)	(0.048)	(0.044)	(0.046)	(0.053)	(0.049)	(0.041)
Existence of an orthogonal test	0.056	0.265***	0.274***	0.251***	0.067*	-0.030	0.040	0.109***	0.199***	0.369***	0.021	0.077**
	(0.043)	(0.053)	(0.054)	(0.047)	(0.036)	(0.045)	(0.043)	(0.041)	(0.049)	(0.053)	(0.043)	(0.036)
Expert recommendations	0.313***	0.351***	0.544***	0.684***	0.518***	0.652***	0.620***	0.753***	0.584***	0.438***	0.643***	0.514***
≥80% Yes	(0.063)	(0.081)	(0.081)	(0.067)	(0.050)	(0.062)	(0.059)	(0.055)	(0.072)	(0.082)	(0.060)	(0.050)

Notes: Coefficients and associated standard errors of 26x8 linear regressions with as dependent variable the inclusion (either 0 or 1) of a gene in a specific program. In each regression, there are three independent variables: the two RUSP categories, and one of the eight gene-disease characteristics (or expert recommendation proportion) listed here. Sample sizes: survey recommendation and orthogonal test (n=649), and evidence base, efficacy, penetrance, disease severity, treatment acceptability and neonatal or infant onset (n=749).

References

Balciuniene, Jorune, Ruby Liu, Lora Bean, Fen Guo, Babi Ramesh Reddy Nallamilli, Naga Guruju, Xiangwen Chen-Deutsch, Rizwan Yousaf, Kristina Fura, Ephrem Chin et al., "At-Risk Genomic Findings for Pediatric-Onset Disorders From Genome Sequencing vs Medically Actionable Gene Panel in Proactive Screening of Newborns and Children," *JAMA Network Open*, 2023, *6* (7), e2326445–e2326445.

Boemer, François, Kristine Hovhannesyan, Flavia Piazzon, Frédéric Minner, Myriam Mni, Valérie Jacquemin, Davood Mashhadizadeh, Noor Benmhammed, Vincent Bours, Adeline Jacquinet et al., "Population-based, first-tier genomic newborn screening in the maternity ward," *Nature Medicine*, 2025, pp. 1–12.

Chen, Ting, Chunna Fan, Yonglan Huang, Jizhen Feng, Yinhong Zhang, Jingkun Miao, Xiaohua Wang, Yulin Li, Cidan Huang, Weiwei Jin et al., "Genomic Sequencing as a First-Tier Screening Test and Outcomes of Newborn Screening," *JAMA Network Open*, 2023, *6* (9), e2331162–e2331162.

Cope, Heidi L, Laura V Milko, Elizabeth R Jalazo, Blythe G Crissman, Ann Katherine M Foreman, Bradford C Powell, Neal A deJong, Jessica Ezzell Hunter, Beth Lincoln Boyea, Ana N Forsythe et al., "A systematic framework for selecting gene-condition pairs for inclusion in newborn sequencing panels: Early Check implementation," *Genetics in Medicine*, 2024, p. 101290.

de la Vega, L Lazo, W Yu, K Machini, CA Austin-Tse, L Hao, CL Blout Zawatsky, H Mason-Suares, RC Green, HL Rehm, and MS Lebo, "A framework for automated gene selection in genomic applications," *Genetics in Medicine*, 2021, *23* (10), 1993–1997.

Gold, Nina B., Sophia M. Adelson, Nidhi Shah, Shardae Williams, Sarah L. Bick, Emilie S. Zoltick, Jessica I. Gold, Alanna Strong, Rebecca Ganetzky, Amy E. Roberts, Melissa Walker, Alexander M. Holtz, Vijay G. Sankaran, Ottavia Delmonte, Weizhen Tan, Ingrid A. Holm, Jay R. Thiagarajah, Junne Kamihara, Jason Comander, Emily Place, Janey Wiggs, and Robert C. Green, "Perspectives of Rare Disease Experts on Newborn Genome Sequencing," *JAMA Network Open*, 05 2023, *6* (5), e2312231–e2312231.

Hao, Chanjuan, Ruolan Guo, Xuyun Hu, Zhan Qi, Qi Guo, Xuanshi Liu, Yuanhu Liu, Yanhua Sun, Xiaofen Zhang, Feng Jin et al., "Newborn screening with targeted sequencing: a multicenter investigation and a pilot clinical study in China," *Journal of Genetics and Genomics*, 2022, *49* (1), 13–19.

Huang, Xinwen, Dingwen Wu, Lin Zhu, Wenjun Wang, Rulai Yang, Jianbin Yang, Qunyan He, Bingquan Zhu, Ying You, Rui Xiao et al., "Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates," *Orphanet Journal of Rare Diseases*, 2022, *17* (1), 66.

Jian, Min, Xiaohong Wang, Yuanyuan Sui, Mingyan Fang, Chenchen Feng, Yingping Huang, Chunhua Liu, Ruidong Guo, Yuanning Guan, Yuxiao Gao et al., "A pilot study of assessing whole genome sequencing in newborn screening in unselected children in China," *Clinical and Translational Medicine*, 2022, *12* (6), e843.

Lian, Wei, Xiaocong Liu, Wensheng Chen, Jun Ki Min, Jae Myung Cha, Min Seob Kwak, Jin Young Yoon, Yunho Jung, Jeong Eun Shin, Hyo-Joon Yang et al., "Implementation of a targeted next-generation sequencing panel for constitutional newborn screening in high-risk neonates," *Yonsei medical journal*, 2019, *60* (11), 1061–1066.

Milko, Laura V, Julianne M O'Daniel, Daniela M DeCristo, Stephanie B Crowley, Ann Katherine M Foreman, Kathleen E Wallace, Lonna F Mollison, Natasha T Strande, Zahra S Girnary, Lacey J Boshe et al., "An age-based framework for evaluating genome-scale sequencing results in newborn screening," *The Journal of pediatrics*, 2019, *209*, 68–76.

Owen, Mallory J, Sebastien Lefebvre, Christian Hansen, Chris M Kunard, David P Dimmock, Laurie D Smith, Gunter Scharer, Rebecca Mardach, Mary J Willis, Annette Feigenbaum et al., "An automated 13.5 hour system for scalable diagnosis and acute management guidance for genetic diseases," *Nature Communications*, 2022, *13* (1), 4057.

Ziegler, Alban, Carrie Koval-Burt, Denise M Kay, Sharon F Suchy, Amber Begtrup, Katherine G Langley, Rebecca Hernan, Laura M Amendola, Brenna M Boyd, Jennifer Bradley et al., "Expanded newborn screening using genome sequencing for early actionable conditions," *JAMA*, 2024.